



HAL
open science

Exploring factors shaping antibiotic resistance patterns in *Streptococcus pneumoniae* during the 2020 COVID-19 pandemic

Aleksandra Kovacevic, David Rm Smith, Eve Rahbé, Sophie Novelli, Paul
Henriot, Emmanuelle Varon, Robert Cohen, Corinne Levy, Laura Temime,
Lulla Opatowski

► **To cite this version:**

Aleksandra Kovacevic, David Rm Smith, Eve Rahbé, Sophie Novelli, Paul Henriot, et al.. Exploring factors shaping antibiotic resistance patterns in *Streptococcus pneumoniae* during the 2020 COVID-19 pandemic. *eLife*, 2024, 13, pp.e85701. 10.7554/eLife.85701 . hal-04604274

HAL Id: hal-04604274

<https://hal.science/hal-04604274>

Submitted on 7 Jun 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Exploring factors shaping antibiotic resistance patterns in *Streptococcus pneumoniae* during the 2020 COVID-19 pandemic

Aleksandra Kovacevic^{1,2*}, David RM Smith^{1,2,3,4}, Eve Rahbé^{1,2}, Sophie Novelli², Paul Henriot^{3,5}, Emmanuelle Varon⁶, Robert Cohen^{7,8,9,10,11}, Corinne Levy^{7,8,10,11}, Laura Temime^{3,5}, Lulla Opatowski^{1,2}

¹Institut Pasteur, Université Paris Cité, Epidemiology and Modelling of Antibiotic Evasion (EMAE) unit, Paris, France; ²Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Inserm U1018, CESP, Anti-infective evasion and pharmacoepidemiology team, Montigny-Le-Bretonneux, France; ³Modélisation, épidémiologie et surveillance des risques sanitaires (MESuRS), Conservatoire national des arts et métiers, Paris, France; ⁴Health Economics Research Centre, Nuffield Department of Health, University of Oxford, Oxford, United Kingdom; ⁵PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France; ⁶Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal de Créteil, Créteil, France; ⁷Institut Mondor de Recherche Biomédicale-Groupe de Recherche Clinique Groupe d'Etude des Maladies Infectieuses Néonatales et Infantiles (IMRB-GRC GEMINI), Université Paris Est, 94000, Créteil, France; ⁸Groupe de Pathologie Infectieuse Pédiatrique (GPIP), 06200, Nice, France; ⁹Unité Court Séjour, Petits Nourrissons, Service de Néonatalogie, Centre Hospitalier, Intercommunal de Créteil, Créteil, France; ¹⁰Association Clinique et Thérapeutique Infantile du Val-de-Marne (ACTIV), 94000, Créteil, France; ¹¹Association Française de Pédiatrie Ambulatoire (AFPA), 45000, Orléans, France

*For correspondence:
aleksandra.kovacevic@pasteur.fr

Competing interest: See page 15

Funding: See page 15

Preprinted: 09 August 2022
Received: 20 December 2022
Accepted: 12 February 2024
Published: 07 March 2024

Reviewing Editor: Marc J Bonten, University Medical Center Utrecht, Netherlands

© Copyright Kovacevic et al. This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract Non-pharmaceutical interventions implemented to block SARS-CoV-2 transmission in early 2020 led to global reductions in the incidence of invasive pneumococcal disease (IPD). By contrast, most European countries reported an increase in antibiotic resistance among invasive *Streptococcus pneumoniae* isolates from 2019 to 2020, while an increasing number of studies reported stable pneumococcal carriage prevalence over the same period. To disentangle the impacts of the COVID-19 pandemic on pneumococcal epidemiology in the community setting, we propose a mathematical model formalizing simultaneous transmission of SARS-CoV-2 and antibiotic-sensitive and -resistant strains of *S. pneumoniae*. To test hypotheses underlying these trends five mechanisms were built into the model and examined: (1) a population-wide reduction of antibiotic prescriptions in the community, (2) lockdown effect on pneumococcal transmission, (3) a reduced risk of developing an IPD due to the absence of common respiratory viruses, (4) community azithromycin use in COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains. Among 31 possible pandemic scenarios involving mechanisms individually or in combination, model simulations surprisingly identified only two scenarios that reproduced the reported trends in the general population. They included factors (1), (3), and (4). These scenarios replicated a nearly 50% reduction in annual IPD, and an increase in antibiotic resistance from 20% to 22%, all while maintaining a relatively stable pneumococcal carriage. Exploring further, higher

SARS-CoV-2 R_0 values and synergistic within-host virus-bacteria interaction mechanisms could have additionally contributed to the observed antibiotic resistance increase. Our work demonstrates the utility of the mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses on AMR dynamics.

Editor's evaluation

The mathematical modeling approach disentangles the impacts of the COVID-19 pandemic on antibiotic resistance in *Streptococcus pneumoniae* in the community setting and identifies the three most plausible driving mechanisms responsible for the observed trends in invasive isolates and pneumococcal carriage. The significance of the findings is important for our understanding of the changed epidemiology of invasive pneumococcal infections during the COVID-19 pandemic. The strength of the evidence is graded as solid, derived from a well-described mathematical model evaluating multiple scenarios.

Introduction

In the early 2020, international responses to the coronavirus disease 2019 (COVID-19) pandemic led to unprecedented worldwide change in population mixing, healthcare-seeking behavior, and infection prevention and control practices. This modified the ecology and epidemiology of many infectious diseases at a global scale. Strong impacts of COVID-19 on infectious disease dynamics have been reported for common viral and bacterial respiratory infections, sexually transmitted pathogens like HIV, vector-borne diseases like dengue, and even non-communicable diseases (*Braunstein et al., 2020; Brueggemann et al., 2021; Chen et al., 2022; Palmer et al., 2020*). Antimicrobial resistance (AMR), however, remains one of the leading threats to global health. In 2019, estimates showed that AMR in clinically relevant bacteria was associated with 4.95 million deaths, of which 1.27 million were described as directly attributable to resistance (*Murray et al., 2022*). Impacts of the COVID-19 pandemic on AMR dynamics remain relatively poorly understood.

A joint report from the WHO and European Centre for Disease Prevention and Control (ECDC) has reported 2020 AMR trends across 29 European countries for eight antibiotic-resistant bacterial pathogens of concern, including *S. pneumoniae* (*European Centre for Disease Prevention and Control and World Health Organization, 2022*). While the situation varies widely across bacterial species, antimicrobial groups, and regions, most European countries, including France, documented an increase in pneumococcal resistance to both penicillin and macrolides between 2019 and 2020. The resistance rates rose from 12.2% in 2019 to 15.6% in 2020 for penicillin and from 14.5% in 2019 to 16.9% in 2020 for macrolides, as reported in the EU/EEA (*European Centre for Disease Prevention and Control and World Health Organization, 2022*). However, increased pneumococcal resistance was accompanied by a sharp worldwide decline in invasive pneumococcal disease (IPD) incidence (*Brueggemann et al., 2021; Shaw et al., 2023*).

Similar declines in bacterial disease during early waves of COVID-19 have been observed in the context of sentinel community-acquired infections in New Zealand (*Duffy et al., 2021*), IPDs in Taiwan (*Chien et al., 2021*) and Hong Kong (*Teng et al., 2022*), and lower respiratory tract infections in China (*Chen et al., 2021*). Yet, surprisingly, a growing number of studies have reported mostly stable pneumococcal carriage throughout the COVID-19 pandemic containment, including among infants in Belgium (*Willen et al., 2021*), children in Vietnam (*Nation et al., 2023*), Serbia (*Petrović et al., 2022*), France (*Rybak et al., 2022*), South Africa (*Olwagen et al., 2024*), and Israel (*Dagan et al., 2023*), adults in Connecticut (*Wyllie et al., 2023*), and households in Seattle (*Bennett et al., 2023*). In contrast, a study conducted in Denmark reported a decrease in pneumococcal carriage among older adults during the COVID-19 lockdown (*Tinggaard et al., 2023*).

Understanding the cause of these trends is not straightforward, as many responses to the COVID-19 pandemic, such as the implementation of non-pharmaceutical interventions (NPIs), changes in healthcare-seeking behavior, and alterations in antibiotic prescribing, occurred over the period (*Knight et al., 2021*). To gain a comprehensive understanding of the changes in AMR epidemiology during the COVID-19 pandemic, it is essential to simultaneously consider a range of scales and indicators. These include the rates of incidence of invasive bacterial diseases (IBDs), the proportion of

antibiotic-resistant isolates among total invasive bacterial isolates, and the prevalence of asymptomatic bacterial carriage in healthy individuals.

Several mechanisms may underlie the explanation of these contrasting observations. First, NPIs implemented to block SARS-CoV-2 transmission, such as lockdowns and mask mandates, may have led to reduced bacterial transmission. Containment measures also massively reduced circulation of common respiratory viruses, which are known to be associated with IBD (*Domenech de Cellès et al., 2019; Smith and Opatowski, 2021*). Second, the lockdown was associated with reductions in primary care consultations (*Homeniuk and Collins, 2021; Read et al., 2023; Zhang et al., 2021*) leading to a global decrease of antibiotic prescriptions (*Högberg et al., 2021*). In contrast, frequent antibiotic prescribing to COVID-19 outpatients may have exacerbated AMR (*Clancy et al., 2020; Knight et al., 2021*). Differences in the duration of pneumococcal carriage may have also played a role (*Lehtinen et al., 2017*). Finally, potential within-host interactions between SARS-CoV-2 and *S. pneumoniae* could also have an impact on infection risk (*Amin-Chowdhury et al., 2021*), although strong evidence for such interactions remains limited (*Wong et al., 2023*).

Mathematical models incorporating the co-transmission of multiple pathogens within the same host population provide a framework for investigating different hypotheses that underlie the observed patterns in antibiotic resistance and incidence of IPD in *S. pneumoniae* and help to enhance our understanding of the mechanisms involved. Co-circulation models have been used previously to disentangle the public health consequences of interactions between pathogens such as influenza and *S. pneumoniae* (*Arduin et al., 2017; Domenech de Cellès et al., 2019; Shrestha et al., 2013*) and could similarly be used to understand impacts of the COVID-19 pandemic on pathogens coinciding with SARS-CoV-2. However, in a systematic PubMed search conducted on 4 December 2023, we identified no epidemiological models describing the simultaneous transmission of SARS-CoV-2 and antibiotic-resistant bacteria specific to the community setting (Appendix 1).

Here, to disentangle how the COVID-19 pandemic has impacted the epidemiological dynamics of antibiotic resistance in *S. pneumoniae*, we propose a mathematical model that formalizes the transmission of SARS-CoV-2 and both antibiotic-sensitive and -resistant strains of *S. pneumoniae* in the community setting, and which includes mechanistic impacts of COVID-19 burden on epidemiological parameters. Through simulation, we assess all possible combinations of these mechanisms to evaluate their overall impact on IPD incidence, antibiotic resistance, and the prevalence of pneumococcal carriage. Furthermore, we assess the changes in the incidence of antibiotic-resistant IPD as we vary the basic reproduction number (R_0) of SARS-CoV-2 during the first COVID-19 outbreak in Europe. We also consider assumed within-host pathogen interactions between SARS-CoV-2 and *S. pneumoniae*.

Results

Antibiotic resistance trends and incidence of invasive pneumococcal disease in 2020

In routine surveillance data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net), most European countries reported an increase in antibiotic resistance in *S. pneumoniae* from 2019 to 2020, as indicated by increases in the proportion of invasive isolates with phenotypic resistance to both penicillin and macrolides (*Figure 1A*). On the contrary, the total number of reported invasive isolates in the EU/EEA decreased by 44.3% from 2019 to 2020 (*European Centre for Disease Prevention and Control and World Health Organization, 2022*) suggesting a decrease in incidence of IPD (*Appendix 2—table 1*).

Invasive pneumococcal isolate data for France provided by the French National Reference Center for Pneumococci (CNRP) revealed similar trends. In France, the total number of reported invasive pneumococcal isolates decreased by 45.1% from 2019 to 2020 (from 1119–614), while antibiotic resistance in *S. pneumoniae* isolates to penicillin and macrolides showed an increasing trend from 26.2% in 2019 to 35.5% in 2020 for penicillin, and from 20.9% in 2019 to 23.0% in 2020 for macrolides (*Figure 1B*). General decreasing trend in antibiotic resistance from 2017 to 2019 in *S. pneumoniae* was interrupted in 2020 (*Figure 1—figure supplement 1*). These variations in antibiotic resistance manifested differently across age, with some age groups showing an increase in antibiotic resistance in 2020 compared to 2019, while others showed no significant change (*Figure 1B*).




Figure 1. Antibiotic resistance trends in invasive *Streptococcus pneumoniae* isolates for the years 2019 and 2020. **(A)** The proportion of invasive *S. pneumoniae* isolates resistant to penicillin and macrolides (azithromycin/ clarithromycin/ erythromycin) reported to EARS-Net (European Antimicrobial Resistance Surveillance Network) for 24 European countries. Error bars show 95% confidence intervals. **(B)** The proportion of invasive *S. pneumoniae* isolates resistant to penicillin (MIC >0.064 mg/L) and macrolides (erythromycin) according to age. Error bars show 95% confidence intervals. The total number of invasive pneumococcal isolates reported in France decreased by 45.1% from 2019 to 2020 (from 1119–614). Data are provided by the French National Reference Center for Pneumococci.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

Source data 1. European trends in antibiotic resistance in *Streptococcus pneumoniae* invasive isolates (2019–2020).

Figure supplement 1. Antibiotic resistance trends in invasive *Streptococcus pneumoniae* isolates in France, 2017–2020.

Coinfection model of SARS-CoV-2 and *Streptococcus pneumoniae*

As mentioned above, several mechanisms may underlie the explanation of these contrasting observations (**Figure 2A**). COVID-19 NPIs may have led to reduced person-to-person bacterial transmission, potentially contributing to reduced rates of IPD incidence. These containment measures also massively reduced circulation of common respiratory viruses and the incidence of influenza-like-illnesses (ILIs). Respiratory viruses are known triggers and risk factors for developing an IBD from otherwise asymptomatic carriage; in that context, their reduction may have led to reduced infection risk (**Domenech de Cellès et al., 2019; Smith and Opatowski, 2021**). Due to reductions in primary care consultations in 2020, 26 European countries reported an estimated average decrease of 18.3% in overall antibiotic consumption, aligning with the global trend of reduced antibiotic prescriptions compared to 2019 (**Högberg et al., 2021**). On the other hand, frequent prescribing of azithromycin, a macrolide antibiotic initially hypothesized to be effective in COVID-19 treatment, has raised concerns for pandemic-associated antimicrobial overuse or misuse and may have exacerbated AMR during and following the first wave of the pandemic (**Clancy et al., 2020; Knight et al., 2021; Kournoutou and Dinos, 2022; Langford et al., 2021; PRINCIPLE Trial Collaborative Group, 2021; Rusic et al., 2021**). There are still uncertainties about pneumococcal ecology and the evolutionary processes that enable the robust coexistence of strains sensitive and resistant to antibiotics. The role of carriage duration, along with the impact of antibiotic consumption, is also not fully understood in this context. Longer carriage




Figure 2. A modelling framework describing the transmission of SARS-CoV-2 and *Streptococcus pneumoniae* in the community setting, in the context of both general antibiotic prescribing and azithromycin prescribing for COVID-19 infected individuals. **(A)** Non-pharmaceutical interventions (NPIs) implemented to control SARS-CoV-2 transmission (lockdown, face mask use, improved hygiene practices, travel restrictions, quarantine, telemedicine, and physical distancing) may also modify transmission of other pathogens, in addition to impacting antibiotic prescribing due to altered inter-individual contact and health-care seeking behavior. **(B)** SEIR (Susceptible-Exposed-Infected-Recovered) model with antibiotic treatment compartments depicts interaction between SARS-CoV-2 infection and antibiotic prescribing, including both general community prescribing and azithromycin prescribing among individuals infected with SARS-CoV-2. **(C)** Diagram depicting how pneumococcal colonization and the community antibiotic prescribing are affected by the COVID-19 pandemic impacts. Initiation of antibiotic treatment is assumed independent of bacterial carriage, reflecting widespread bystander selection for commensal bacteria like *S. pneumoniae*. For a complete modeling framework, see section S2 in Supporting Information.

duration of antibiotic-resistant pneumococcal strains is a proposed explanation for this coexistence (Lehtinen et al., 2017). If so, antibiotic-resistant pneumococcal strains may have had an advantage during the lockdown period due to smaller clearance rates, ultimately leading to an increase in antibiotic resistance. Finally, among individuals with COVID-19, potential within-host interactions between SARS-CoV-2 and *S. pneumoniae* could also have had an impact on bacterial colonization and infection dynamics (Amin-Chowdhury et al., 2021).

To test mechanistic impacts of responses to the COVID-19 pandemic on pneumococcal epidemiology, we developed a compartmental, deterministic transmission model describing infection with SARS-CoV-2 being introduced on 1 Jan 2020 (Figure 2B) after colonization with *S. pneumoniae* reached an equilibrium in a large, well-mixed human population (Figure 2C). Two lockdowns were implemented in the model in agreement with the two lockdowns implemented in France in 2020. The model was parameterized to *S. pneumoniae* and five mechanisms were built in into the model: (1) a population-wide reduction of antibiotic prescriptions in the community by 18% due to the reduced healthcare-seeking behavior, (2) lockdown reducing pneumococcal transmission by 25%, (3) a reduced risk of developing an IPD from asymptomatic carriage due to the absence of common respiratory viruses during the first lockdown (reduced by a factor $IPD_{risk} = 0.2$), which continues after the first lockdown, albeit at a diminished level ($IPD_{risk} = 0.4$), (4) community azithromycin use in 10% of COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains giving them a fitness advantage over antibiotic-resistant strains (40 vs 30 days).

Exploring the mechanisms and identifying the optimal scenario for explaining reported trends

We conducted assessments on five distinct hypotheses, each characterized by a precise underlying mechanism, and explored these hypotheses in combination within 31 pandemic scenarios, along with two pre-pandemic (baseline) scenarios, which assume no SARS-CoV-2 circulation in the population and allow for the same 30-day carriage duration (pre-pandemic 1) of both antibiotic-sensitive and -resistant strains ($d_s = d_r$) or a longer, 40-day carriage duration (pre-pandemic 2) of -resistant strains ($d_s > d_r$) (**Table 1**).

We assessed how different combinations of mechanisms may impact: (i) a change in the annual IPD incidence as compared to the pre-pandemic (baseline) period, (ii) antibiotic resistance rate in IPDs, defined as the annual number of antibiotic-resistant IPD cases over the total number of IPD cases, and (iii) daily prevalences of antibiotic-resistant and total pneumococcal carriage in a simulated population of 100,000 individuals (see **Appendix 2—table 2** for parameter values). To identify scenarios most compatible with the reported trends, results from model simulations were compared to reported data trends from France in 2020 and more broadly to general EU/EEA reported trends that followed similar patterns. Surprisingly only two scenarios were compatible with reported trends. Scenarios S19 and S29 univocally reproduced increased antibiotic resistance in the general population (AR%) accompanied by a reduction in the annual IPD incidence by almost 50% (IPD inc) with generally stable pneumococcal carriage prevalence in healthy individuals during lockdown (Sp.). In contrast, model simulations revealed that a reduction in the community antibiotic consumption alone (−18%) could not explain the reported trends and generally led to a reduction of antibiotic resistance (**Table 1**, see scenario S1). Assuming a longer duration of antibiotic-resistant pneumococcal carriage alone did not explain either the rise in antibiotic resistance (**Table 1**, see scenario S5). Hypothesizing that lockdown reduced the transmission of pneumococcal carriage (by 25%) in addition to a reduced community antibiotic prescribing did not seem probable since, in simulations, this yielded a major reduction in pneumococcal carriage during containment measures in all scenarios where this mechanism was implemented. On the other hand, considering an indirect impact of lockdown on pneumococcal carriage where we implemented a reduction factor for the risk of developing and IPD from otherwise asymptomatic carriage due to the absence of viral respiratory infections during ($IPD_{risk} = 0.2$) and after lockdown ($IPD_{risk} = 0.4$) reproduced the reported reduction in the annual IPD incidence while maintaining a stable prevalence of pneumococcal carriage during lockdown (**Table 1**, see scenario S3). By itself however, this scenario did not allow to observe an increase in antibiotic resistance.

When we combined reduced antibiotic prescribing and a reduced risk of developing an IPD with community azithromycin use in a proportion of COVID-19 infected individuals, which remains in the body for an additional 15.5 days after the last dose, in a single scenario, this scenario satisfied the observed trends in AMR (**Table 1**, see scenario S19). A similar outcome was observed in scenario S29 when adding a longer carriage duration of antibiotic resistant strains on top of this, however, in the absence of community azithromycin use in COVID-19 infected (**Table 1**, see scenario S1, S5, S3, S19, and S20) trends of increasing antibiotic resistance cannot be reproduced. Therefore, our best model scenario for describing the observed trends combined: (1) a reduction in the overall community antibiotic consumption; (2) the assumption that lockdown effectively reduced SARS-CoV-2 transmission including transmission of other respiratory viruses, but not pneumococcal carriage transmission, indirectly reducing the risk of developing an IPD; (3) either identical or longer carriage durations of antibiotic-resistant strains compared to antibiotic-sensitive strains, and (4) the community azithromycin use in a proportion of COVID-19 infected individuals.

Effect of age

Next, we used the pandemic scenario S19 that best explains the reported trends to test the model using different parameter combinations to mimic different subpopulations (children and the elderly) considering that SARS-CoV-2 infection risk, pneumococcal disease risk, disease severity, bacterial carriage prevalence, and antibiotic prescribing are all highly heterogeneous across age groups. Using scenario S19, we initialized the model with lower and higher baseline carriage prevalence (10%, 20%, and 30%) (**Cohen et al., 2023; Rose et al., 2021; Rybak et al., 2022; Tinggaard et al., 2023; Wang et al., 2017**), we varied durations of pneumococcal carriage (20, 30, and 45 days), pneumococcal invasion rate, and considered reductions of antibiotic consumption at various levels (−13%, −18%, and

Table 1. Five mechanisms implemented in 31 pandemic scenarios proposed to explain the reported trends of IPD incidence, antibiotic resistance, and pneumococcal carriage in *S. pneumoniae*.

Scenarios explore all possible combinations of mechanisms proposed to test hypotheses that can explain the reported trends of annual invasive pneumococcal disease incidence (annual no. of cases per 100,000 inhabitants), antibiotic resistance (% of annual antibiotic-resistant IPD cases among total IPD cases), and % change in the pneumococcal carriage prevalence at the end of the first 60-day lockdown compared the prevalence before the lockdown. Model simulations were initiated assuming the initial 20% antibiotic resistance. Two pre-pandemic scenarios assume no SARS-CoV-2 circulation in the population and allow for the same 30-day carriage duration of both antibiotic-sensitive and -resistant strains ($d_S = d_R$) or a longer, 40-day carriage duration of -resistant strains ($d_R > d_S$). When implemented, these five mechanisms assume 18% reduction in community antibiotic prescribing, a reduced risk of developing an IPD during (0.2) and after the first lockdown (0.4), a 25% reduction in transmission of pneumococcal carriage during the first lockdown, a 10% of azithromycin use among COVID-19 infected individuals, and a longer 40-day carriage duration of -resistant strains. For a full list of parameters see **Appendix 2—table 2**. Reported trends in European countries showed a decrease in annual IPD incidence by 44.3% on average, an increase in antibiotic resistance, and generally stable asymptomatic pneumococcal carriage in healthy individuals during the first lockdown period. Only scenarios S19 and S29 fulfill all three reported trends during the COVID-19 pandemic in 2020 simultaneously while accounting for the reported reduction in community antibiotic prescribing (d_S = carriage duration of antibiotic-sensitive pneumococcal strains; d_R = carriage duration of antibiotic-resistant pneumococcal strains; PENI = penicillin; ERY = erythromycin).

Scenarios	Mechanisms					IPD inc.	AR (%)	Sp. (%)
	1	2	3	4	5			
Pre-pandemic 1: ($d_S = d_R$)						10.8	20.0	NA
Pre-pandemic 2: ($d_R > d_S$)					x	11.3	20.0	NA
Pandemic: S1	x					10.9	19.2	+1.3
S2		x				8.9	20.1	-36.1
S3			x			5.9	20.0	0
S4				x		9.9	23.7	-9.1
S5					x	11.3	20.0	0
S6	x	x				9.1	19.4	-35.2
S7	x		x			6.0	19.4	+1.3
S8	x			x		10.1	22.9	-8.0
S9	x				x	11.5	19.3	+1.3
S10		x	x			5.2	20.0	-36.1
S11		x		x		8.9	20.1	-36.1
S12		x			x	9.4	20.9	-34.3
S13			x	x		5.6	22.5	-9.1
S14			x		x	6.2	20.0	0
S15				x	x	10.4	23.4	-9.1
S16	x	x	x			5.3	19.6	-35.2
S17	x	x		x		8.3	22.4	-41.3
S18	x	x			x	9.6	20.3	-33.5
S19	x		x	x		5.7	22.0	-8.0
S20	x		x		x	6.3	19.5	+1.3
S21	x			x	x	10.6	22.7	-7.9
S22		x	x	x		5.0	22.0	-42.1
S23		x	x		x	5.5	20.6	-34.3

Table 1 continued on next page

Table 1 continued

S24		x		x	x	8.7	23.9	−40.2
S25			x	x	x	5.9	22.3	−9.1
S26	x	x	x	x		5.0	21.6	−41.3
S27	x	x	x		x	5.6	20.1	−33.5
S28	x	x		x	x	8.8	23.2	−39.4
S29	x		x	x	x	5.9	21.8	−7.9
S30		x	x	x	x	5.2	22.5	−40.2
S31	x	x	x	x	x	5.3	22.1	−39.4

REPORTED TRENDS:	IPD inc.	AR (%)	Sp. (%)
Pre-pandemic (FR, 2019)	10.5 [10.3–10.7]	26.2 (PENI) and 20.9 (ERY)	NA
Pandemic (FR, 2020)	5.8 [5.7–5.9]	35.5 (PENI) and 23.0 (ERY)	Stable
Pandemic (EU/EEA, 2020)			
General trends	Decrease by 44.3% on avg.	Majority of EU countries report an increase	Generally stable

Mechanisms: (1) Reduced community antibiotic prescribing; (2) Lockdown effect on reducing transmission of *S. pneumoniae*; (3) Reduced risk of developing an IPD; (4) Community azithromycin use in COVID-19 infected individuals; (5) Longer carriage duration of antibiotic-resistant pneumococcal strains.

−39%) consistent with the French data along with a range of community azithromycin use in COVID-19 infected (0–20%). For a full list of parameters see **Appendix 2—table 2**. Simulations showed that annual IPD incidence decreased between 43% and 51% compared to the pre-pandemic (baseline) scenario for children, the elderly, and the general population (**Figure 3**, grey bars). Although the overall antibiotic prescribing in the community was reduced (between 13% and 39%), antibiotic resistance is expected to increase (from 20.1% up to 23.6% in the elderly and from 32.8% up to 36.0% in children) compared to the pre-pandemic period in all age groups and in all scenarios where azithromycin was used in COVID-19 infected individuals (**Figure 3**, red bars). Daily prevalence of total pneumococcal carriage remained relatively stable, exhibiting higher levels of decrease with increased azithromycin use, while the prevalence of antibiotic-resistant pneumococcal carriage is expected to increase since clearance of antibiotic-susceptible strains due to azithromycin use shifts the competitive balance in favor of the existing resistant strains (**Figure 3**, third panel).

General trends produced in model simulations using scenario S19 remained unchanged across different age groups. The extent of the impact depended on the combined magnitude of a decrease in the general antibiotic use in the community and a degree of azithromycin use in COVID-19 infected individuals belonging to a particular age group or a subpopulation. In the elderly (≥ 65 years-old) and the general population, antibiotic resistance is expected to increase due to azithromycin use in COVID-19 infected. Black arrows indicate model outcomes that approximate the reported trends in antibiotic resistance in France for different age groups including general population (**Figure 3**). Only in instances when there was no azithromycin use in COVID-19 infected individuals, we observed a decrease in antibiotic resistance relative to the pre-pandemic period (e.g. children <5 years-old). When combining the largest decrease in overall antibiotic use with no or minimal azithromycin use in COVID-19 infected individuals, we expect to see the largest decrease or no change in antibiotic resistance relative to the pre-pandemic period.

Effect of SARS-CoV-2 basic reproduction number (R_0) and within-host pathogen interactions on AMR

Considering that model simulations reproduced an absolute increase in antibiotic resistance comparable to that of 2% reported for macrolides in France but did not reproduce the reported larger increase in penicillin resistance, which was more than a 9% rise (35.5% relative increase) in France, we




Figure 3. Annual incidence of invasive pneumococcal disease (IPD), antibiotic resistance (AR%), and pneumococcal carriage prevalence for three different subpopulations. **(A)** The elderly (≥ 65 years-old) **(B)** general population (all ages), and **(C)** children (< 5 years-old). Using pandemic scenario S19, which includes a combination of three different mechanisms: reduced community antibiotic prescribing, a reduced risk of developing an IPD, and community azithromycin use in COVID-19 infected individuals, we ran model simulations for three different subpopulations. For a full list of parameter values see **Appendix 2—table 2**. Annual IPD incidence (grey bars) decreased between 43% and 51% relative to the pre-pandemic (baseline) period with magnitude of a decrease depending on an age group and the level of azithromycin use in COVID-19 infected individuals. Antibiotic resistance (red bars) increased compared to the pre-pandemic (baseline) period in all age groups whenever azithromycin was used in COVID-19 infected. Black arrows indicate model outcomes that approximate the reported trends in antibiotic resistance in France for different age groups. Daily prevalence of total pneumococcal carriage remained relatively stable (solid-colored lines), exhibiting higher levels of decrease with increased azithromycin use. The prevalence of antibiotic-resistant pneumococcal carriage increased (dashed colored lines) over time in relation to SARS-CoV-2 outbreak (black dashed line) and higher azithromycin use. Highlighted time intervals (days 75–135 and 305–365) represent two lockdown periods.

explored additional factors that may have amplified this increase. Using model scenario S19, we show that an association between higher values of SARS-CoV-2 R_0 and a greater percentage of COVID-19 infected individuals taking azithromycin leads to increased cumulative incidence of antibiotic-resistant IPDs and elevated antibiotic resistance (**Figure 4A**). For example, if pre-lockdown R_0 of SARS-CoV-2 was 3.8 instead of 3.2, model simulations predict an increase of 3.5% (23.5%) in antibiotic resistance




Figure 4. The impact of varying SARS-CoV-2 R_0 and percentage of COVID-19 infected individuals taking azithromycin in scenario S19 on antibiotic resistance (%) and the annual incidence of antibiotic-resistant invasive pneumococcal disease (IPD). Hypothetical within-host interactions contribute to an excess incidence of antibiotic-resistant IPDs. **(A)** Cumulative incidence of antibiotic-resistant IPDs and antibiotic resistance increase with greater values of SARS-CoV-2 R_0 and higher percentage of the COVID-19 infected individuals taking azithromycin. The reproduction number for SARS-CoV-2 (R_0) in the community corresponds to the most common estimates of R_0 in France and other European countries ranging from $R_0=2-4$ (Allieta et al., 2022; D’Arienzo and Coniglio, 2020; Di Domenico et al., 2020; Flaxman et al., 2020; Liu et al., 2020; Roux et al., 2020; Salje et al., 2020). **(B)** Annual excess in cumulative antibiotic-resistant IPD incidence in scenario S19 due to synergistic within-host ecological interactions compared to the same scenario with no within-host interactions and no azithromycin use (1.17 resistant IPD cases/100,000 inhabitants). A rate of disease progression increased by a factor $\psi_c = 1$ (no within-host interaction) and $\psi_c = 40$ in scenario S19 applied to the general population assuming azithromycin use in 10% of the infected individuals resulted in approximately 0.06 and 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of 1 year, respectively, compared to the scenario S19 assuming no within-host interaction and no azithromycin use (indicated by the black arrow). For more details, see **Appendix 2—figure 1**.

from the pre-pandemic levels instead of 2%. As the R_0 value increases, the impact of azithromycin use becomes more pronounced.

Assuming within-host interactions where SARS-CoV-2 infection favors progression from pneumococcal colonization to disease ($\psi_c > 1$), we found that surges in COVID-19 cases accompanied by increasing levels of azithromycin use lead to excess number of cases caused by antibiotic-resistant

strains. Indeed, a rate of disease progression increased by a factor $\psi_c = 40$ in scenario S19 with 10% of infected using azithromycin applied to the general population results in approximately 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of 1 year compared to 0.06 additional cases if there are no within-host interactions (**Figure 4B**). This represents 5% rise in resistance from the pre-pandemic levels (25% relative increase).

Discussion

We propose a novel co-circulation model describing the spread of SARS-CoV-2 and antibiotic-resistant bacteria in a community setting to show how human behavioral responses to the COVID-19 pandemic can differentially impact antibiotic resistance. Our model simulations assessed different hypotheses proposed to explain the observed trends of antibiotic resistance, IPD incidence, and pneumococcal carriage. We identified the most plausible mechanisms underlying the observed patterns of resistance and disease incidence, showing how lockdowns indirectly substantially reduce the incidence of IPD, while surges in COVID-19 cases accompanied by antibiotic prescribing in COVID-19 infected individuals increase antibiotic resistance.

Many studies have reported trends on the incidence of community-acquired bacterial infections since the onset of the pandemic (**Brueggemann et al., 2021; Shaw et al., 2023**). There was a significant reduction in the risk of invasive disease caused by *S. pneumoniae* (risk ratio 0.47; 95% CI 0.40–0.55; **Shaw et al., 2023**). Initially, this observation seemed to support the hypothesis that NPIs implemented to control SARS-CoV-2 transmission may have simultaneously reduced the incidence of bacterial infections by preventing bacterial transmission and acquisition (**Brueggemann et al., 2021; Kadambari et al., 2022**). Indeed, the scenario of lockdown impact on pneumococcal transmission reproduced such trends. However, incorporating a mechanism of reduced risk for developing an IPD due to the absence of circulation of common respiratory viruses led to similar estimates of the relative reduction in IPD incidence as reported in the EU/EEA for 2020 (**Brueggemann et al., 2021; European Centre for Disease Prevention and Control and World Health Organization, 2022**). This finding, coupled with the outcome of other studies that found a generally stable pneumococcal carriage prevalence in healthy individuals, both children and adults, during COVID-19 containment measures (**Nation et al., 2023; Petrović et al., 2022; Rybak et al., 2022; Willen et al., 2021; Wyllie et al., 2023**), supports the alternative hypothesis. This explanation accounts for the decreased incidence of IPD, rather than attributing it to reduced pneumococcal transmission, which resulted in a significant reduction in carriage according to the simulations (**Smith and Opatowski, 2021**). Furthermore, a study in Vietnam found that reductions in IPD associated with NPIs may be due to reductions in overall pneumococcal carriage density rather than carriage prevalence, driven by reductions in capsular pneumococcal carriage density frequently implicated in IPD (**Nation et al., 2023**). Considering that common respiratory viruses such as influenza increase pneumococcal carriage density, which contributes to transmission and disease, this hypothesis seems plausible (**Alpkvist et al., 2015; Diavatopoulos et al., 2010; McCullers et al., 2010; Short et al., 2012; Wolter et al., 2014**).

Globally, community antibiotic consumption dropped during the first year of the COVID-19 pandemic compared to the pre-pandemic period. Decreasing temporal trends were observed in England (**Hussain et al., 2021**), Canada (**Mamun et al., 2021**), the United States (**Buehrle et al., 2021**), China (**Zhang et al., 2021**), South Korea (**Ryu et al., 2021**), New Zealand (**Duffy et al., 2021**), and across European countries (**Högberg et al., 2021**). In France in particular, the number of antibiotic prescriptions decreased by 18.2% in the general population; however, this reduction ranged from 13% to 39% for the oldest and youngest age groups, respectively (**Bara et al., 2022**). These trends in antibiotic prescribing may largely be explained by reduced incidence of seasonal respiratory tract infections and reduced primary care consultations (**Andrews et al., 2022; Homeniuk and Collins, 2021**). On the other hand, the advent of telemedicine, pandemic-induced patient stress, and increased antibiotic demand may have partly offset prescription reductions due to decreased consultations and healthcare-seeking behavior (**Hsu, 2020; Read et al., 2023**). In a global analysis of antimicrobial sales, Khouja et al. found that antibiotic consumption initially increased by approximately 7% in March 2020, prior to subsequent declines through to August 2020 (**Khouja et al., 2022**). While overall antibiotic prescribing may have decreased, prescription of specific antibiotics has increased, particularly those associated with COVID-19 patient management. Across continents, a rise of 10% in

monthly COVID-19 cases exhibited a correlative trend with elevated macrolide sales of 0.8%, 1.3%, and 1.5% in Europe, North America, and Africa, respectively (**Nandi et al., 2023**).

Community consumption of azithromycin, a macrolide, increased during the first year of the pandemic in multiple countries with significant variation across geographic locations and with greatest prescribing among older patients (**Bara et al., 2022; Bednarčuk et al., 2023; Bogdanić et al., 2022; Crisafulli et al., 2021; Parveen et al., 2020; Weill et al., 2021**). In an outpatient setting in southern Italy between February 2020 and January 2021, azithromycin represented 42.1% of all drug prescriptions to individuals diagnosed with COVID-19, while all other antibiotics combined represented just 20.9% (**Crisafulli et al., 2021**). A study in northwest London across two epidemic waves between January and August 2020 found that, among COVID-19 patients prescribed an antibiotic by a general practitioner during the study period, 31.5% received their prescription within 14 days of a positive SARS-CoV-2 test (**Zhu et al., 2021**). Two large USA-based studies have also described early pandemic antibiotic prescribing among COVID-19 patients. From April 2020 to April 2021, approximately 30% of outpatient COVID-19-related visits among Medicare beneficiaries (≥ 65 years-old) have resulted in a filled antibiotic prescription, 50.7% of which were for azithromycin (**Tsay et al., 2022**). For 0-to-5 year-olds and 45-to-64 year-olds, 4% and 16% of outpatient COVID-19-related visits have resulted in a filled antibiotic prescription, respectively (**Wittman et al., 2023**). In the Alsace region in France, there was a clear peak azithromycin prescribing during the first wave of the COVID-19 (**Danion et al., 2023**). During the first lockdown in France, community azithromycin consumption increased by 25.9%, with the increase varying from 13.4% to 47.3% depending on the week (**Weill et al., 2021**), while the overall number of azithromycin prescriptions across France in 2020 increased by 10.1% relative to 2019 (**Bara et al., 2022**). Azithromycin treatment usually lasts 3–5 days depending on the disease, but the drug stays in the system for about 15.5 days after the last dose due to the long half-life of more than 60 hr (**Foulds et al., 1990; Girard et al., 2005**). On the other hand, penicillin has an elimination half-life of approximately 1.4 hr and leaves the body in 7.7 hr after the last dose. This suggests that if azithromycin consumption increased during the first year of the pandemic, antibiotic exposure time also increased as a result, although the overall number of antibiotic prescriptions decreased. Moreover, the use of azithromycin has been associated with selection of both macrolide and non-macrolide resistance (**Doan et al., 2020**). In a study investigating the direct effect of antibiotic exposure on resistance in the oral streptococcal flora of healthy volunteers, use of azithromycin (500 mg once daily for 3 days) significantly increased the proportion of macrolide-resistant streptococci in healthy individuals (**Malhotra-Kumar et al., 2007**). Resistance peaked at day four in the azithromycin group and this increase remained significantly higher in the azithromycin group than in the placebo group until day 180 (**Malhotra-Kumar et al., 2007**). A clinical trial of mass azithromycin distributions for treating trachoma in Ethiopia resulted in an increase in resistant *S. pneumoniae* isolates among children under the age of 10 (**Keenan et al., 2018; Keenan et al., 2015**).

Our model simulations show that antibiotic resistance increases with surges in SARS-CoV-2 infections when there is a corresponding increase in azithromycin use, but that lockdowns can moderate this increasing trend by effectively limiting transmission of SARS-CoV-2 (**Salje et al., 2020**). Conversely, surges in azithromycin prescribing during SARS-CoV-2 outbreaks in the absence of effective measures to prevent transmission, as reported in certain regions and pandemic periods, may cause substantial increases in antibiotic resistance. Our model successfully captured the main trends of antibiotic resistance and IPD incidence observed in Europe in 2020 for *S. pneumoniae*. However, not all European countries reported an increase in antibiotic resistance. This inter-country heterogeneity may not be due only to heterogeneity of antibiotic use as shown in our model but may be attributed to other pandemic factors not directly implemented or assumed in the model scenario, such as different adherence to COVID-19 control measures across countries and different age groups, including impacts on disease surveillance and data reporting during the pandemic. Real-life scenarios are significantly more complicated and involve multiple alterations of many pandemic factors at different points in time and heterogeneity across populations (e.g. antibiotic prescribing increases in some demographic groups and decreases in others, multiple lockdowns, curfews, or telework).

In our model simulations, we used SARS-CoV-2 parameter value $R_0=3.2$ (**Liu et al., 2020**) in the absence of population immunity, best reflecting epidemiological dynamics from early in the pandemic. The most common estimates of SARS-CoV-2 R_0 in France and other European countries ranged from $R_0=2-4$ (**Flaxman et al., 2020; Liu et al., 2020**). Modeling results suggest that higher SARS-CoV-2

R_0 estimates combined with higher proportion of COVID-19 infected individuals using azithromycin exacerbated impacts of COVID-19 on antibiotic resistance (**Figure 4A**). However, the overall impacts of COVID-19 on AMR are difficult to predict, likely vary over the short, medium, and long term, and depend on the organism, setting, and subpopulation considered.

SARS-CoV-2 bacterial coinfection has been reported relatively rarely over the course of the pandemic, suggesting that most COVID-19 patients probably do not require antibiotic therapy (**Garcia-Vidal et al., 2021; Karami et al., 2021; Langford et al., 2020**), although extensive prophylactic antibiotic use may have limited observed co-infection incidence. The inflammatory immune response resulting from COVID-19 likely predisposes patients to subsequent progression to an IBD to some extent (**Sender et al., 2021**), but antibiotic use may also favor progression to IBD for patients colonized with drug-resistant strains (**Baggs et al., 2018**). We do not explicitly model the dynamics of interaction since strong evidence for such interactions remains limited (**Wong et al., 2023**). The results presented in **Figure 4B** suggest that such within-host interactions could have important consequences for the resistant IPD incidence during COVID-19 waves, especially in the elderly and high-risk groups. The model's structure allows for easy integration of mechanistic interactions as more information becomes available on this phenomenon.

Our study focused on the general community, but COVID-19 distinctly influenced AMR in hospitals and long-term care facilities. Extensive antibiotic use in COVID-19 patients and disruptions to antibiotic stewardship programs may have increased antibiotic-resistant carriage in these settings. A meta-analysis conducted on studies published until June 2020 found that 68–81% of hospitalized COVID-19 patients and 74–94% in intensive care received antibiotics (**Monnet and Harbarth, 2020**). The disorganization in hospitals during the COVID-19 pandemic might have reduced antibiotic resistance surveillance, allowing resistant organisms to spread. However, the early implementation of antibiotic stewardship programs in March 2020, patient isolation, and widespread use of personal protective equipment (PPE) have mitigated this increase to some degree (**Henig et al., 2021; Monnet and Harbarth, 2020; Seaton et al., 2020; Van Laethem et al., 2021**). Models analyzing these impacts in hospitals contribute to understanding COVID-19's specific role in the antibiotic resistance burden in different settings (**Smith et al., 2023**).

A limitation of our model is the lack of age structure and contact patterns between age groups, as SARS-CoV-2 infection risk, pneumococcal disease risk, disease severity, bacterial carriage prevalence and antibiotic prescribing are all highly heterogeneous across age groups. While this choice was made to keep the model as simple as possible, we tested the model using different parameter combinations to mimic different subpopulations (children and ≥ 65 years-old). This included varying durations of pneumococcal carriage, initializing the model with lower and higher baseline carriage prevalence, considering reductions of general antibiotic consumption at various levels, and varying a percentage of COVID-19 infected individuals using azithromycin. Simulations of the different age groups individually interestingly reproduced realistic trends by age.

In conclusion, we introduce the first epidemiological model outlining the impact of the COVID-19 pandemic on the dynamics of AMR in the community. Our work demonstrates the utility of mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses AMR dynamics. While our model was structured and parameterized based upon *S. pneumoniae*, its adaptability allows for application to various bacteria and epidemiological scenarios in the community (e.g. impacts of SARS-CoV-2-bacteria interactions in the context of seasonal outbreaks of endemic pathogens). Future research would benefit from fitting the model to real-world data for different bacterial species to enhance our understanding of AMR trends.

Methods

***Streptococcus pneumoniae* surveillance data**

Antibiotic resistance trends reported in 2019 and 2020, provided by EARS-Net (European Antimicrobial Resistance Surveillance Network) were acquired from a joint 2022 report on AMR during 2020 by WHO and ECDC (**European Centre for Disease Prevention and Control and World Health Organization, 2022**). The annual incidence of *S. pneumoniae* invasive isolates for 2019 and 2020 was measured as the number of invasive isolates from blood or cerebrospinal fluid. The proportion of resistant isolates represents the proportion of isolates with phenotypic resistance to penicillin and

macrolides using standardized bacterial culture methods and EUCAST breakpoints. Out of 28 European countries that reported antibiotic resistance data for *S. pneumoniae*, 24 countries had enough samples to establish 2019–2020 resistance trends for penicillin and macrolides. The resistance data for France, which were subsequently analyzed, were provided by the CNRP (The French National Reference Center for Pneumococci).

Model structure

We developed a pathogen co-circulation model (**Appendix 2—figure 2**) written using systems of ordinary differential equations (ODEs) (Appendix 2—Equations; code available on [GitHub](#), copy archived at [Kovacevic, 2024](#)). The model simultaneously describes potential infection with SARS-CoV-2 and colonization with antibiotic-sensitive and/or -resistant strains of *S. pneumoniae* in a well-mixed community population. SARS-CoV-2 infection is modeled by a Susceptible-Exposed-Infectious-Recovered (SEIR) process where individuals become exposed to SARS-CoV-2 at rate β_C upon contact with other infected individuals. Infection begins with a non-infectious exposed period lasting $1/\epsilon$ days and is followed by an infectious period lasting $1/\gamma^C$ days, eventually leading to recovery and immunization against future re-infection. Waning immunity and competitive multi-strain SARS-CoV-2 dynamics are not considered.

Individuals in S, E, I, and R compartments can be uncolonized with *S. pneumoniae* (U), colonized with either a drug-sensitive (C^S) or a drug-resistant strain (C^R), or co-colonized with two strains (C^{SS} , C^{RR} , C^{SR}). Colonization with each respective strain is acquired at rates β_S and β_f upon contact with other colonized individuals (**Appendix 2—table 2**). We assume a metabolic cost of resistance, whereby the drug-resistant strain has a reduced intrinsic transmission rate relative to the drug-sensitive strain due to reduced fitness, f . Bacterial carriage is cleared naturally after an average duration of $\frac{1}{\gamma^S} = \frac{1}{\gamma^R} = \frac{1}{\gamma^{SR}} = \frac{1}{\gamma^{SS}} = \frac{1}{\gamma^{RR}}$ days, which we assume to be the same for all types of carriers in our baseline scenario (in the scenarios assuming longer carriage duration of antibiotic-resistant strains, $\frac{1}{\gamma^S} = \frac{1}{\gamma^{SS}}$ and $\frac{1}{\gamma^R} = \frac{1}{\gamma^{SR}} = \frac{1}{\gamma^{RR}}$). We further assume that some share of the population is exposed to antibiotics at any given time, independent of bacterial carriage, with individuals initiating antibiotic therapy at rate τ , which lasts for an average duration of $\frac{1}{r}$ days. Another model assumption is that a proportion p_{az} of those infected with COVID-19 in the community (between 0% and 20% of individuals in an I compartment) receive azithromycin prescription from general practitioner reflecting azithromycin prescriptions in the early pandemic, while the rest of the infectious individuals ($1 - p_{az}$) are exposed to the baseline antibiotic therapy. We assume baseline treatment duration of 7 days, on average, regardless of the antibiotic prescribed and without any assumed persistence of the antibiotic in the system after the last dose $\frac{1}{r}$. In case of antibiotic treatment with azithromycin for COVID-19 infected individuals we assume the treatment lasts three days with antibiotics remaining in the system for additional 15.5 days after the last dose for a total of 18.5 days of antibiotic exposure where COVID-19 recovered individuals R_{az} treated with azithromycin retain azithromycin in their system for an additional 11.5 days $\frac{1}{r_{az}}$ after COVID-19 recovery. Individuals treated with antibiotics are unable to acquire the sensitive strain. Antibiotics are assumed to clear colonization with sensitive strains at a rate ω while having no direct impact on colonization with resistant strains. This bacterial colonization process results in antibiotic selection for resistance via competition for limited hosts, facilitates epidemiological coexistence between strains and is adapted from previous models of *S. pneumoniae* ([Colijn et al., 2010](#); [Lipsitch et al., 2009](#); [Mulberry et al., 2020](#)). For a full list of parameter values see **Appendix 2—table 2**.

Simulation in an early COVID-19 pandemic context

ODEs were integrated numerically using the R package `deSolve` to simulate and quantify epidemiological dynamics ([Soetaert et al., 2010](#)). First, bacterial dynamics were simulated until endemic equilibrium was achieved, under the assumption that *S. pneumoniae* was at endemic equilibrium upon the emergence of COVID-19. Second, using equilibrium states as initial conditions and re-initializing simulation time to $t=0$, a single SARS-CoV-2 infected individual was introduced into the population and ODEs were again integrated numerically to $t=365$ days. Parameter values used for simulation were taken from prior studies prioritizing French data and are provided in **Appendix 2—table 2**.

These simulations were conducted in the context of an ‘early pandemic scenario’ coinciding with the implementation of population-wide NPIs to slow SARS-CoV-2 transmission. This was conceived as the implementation of two 60 day lockdown periods starting on day 75 and on day 305 in response to the simulated surge in COVID-19 cases. Lockdowns were assumed to have three major potential

impacts on population behavior and, in turn, the transmission dynamics of SARS-CoV-2 and *S. pneumoniae*. These impacts were incorporated into simulations by modifying epidemiological parameters in the model coincident with lockdowns. Three such modifications were considered and switched on and off, considering all possible combinations. First, lockdown led to reduced SARS-CoV-2 transmissibility by a factor θ_c . Second, lockdown led to a population-wide change in antibiotic initiation rate by a factor a (representing modified healthcare-seeking behavior leading to a reduction in the number of antibiotic prescriptions). Finally, lockdowns changed the pneumococcal disease risk by a factor IPD_{risk} (representing a reduced risk of developing an IPD due to the absence of other respiratory viruses).

Effect of SARS-CoV-2 basic reproduction number (R_0) on AMR

Impacts of SARS-CoV-2 on antibiotic-resistant IPD incidence may also depend on the characteristics of locally circulating SARS-CoV-2 R_0 . To account for potential impacts of SARS-CoV-2 transmissibility and azithromycin use in the community, in simulations we varied (i) values of R_0 (basic reproduction number) for SARS-CoV-2 in France ($2 \leq R_0 \leq 4$) and (ii) the proportion of the COVID-19 infected individuals using azithromycin at simulation outset (from 0% to 20%).

Effect of within-host interactions on AMR

SARS-CoV-2 infection may impact progression from bacterial colonization to IBD at the within-host level. To incorporate this mechanism in our model, we included a within-host interaction term in scenario S19: the ecological interaction term (ψ_c) increases the rate of progression to invasive disease among colonized individuals who are also infected with SARS-CoV-2. The equations for calculating daily IPD incidence assuming within-host interactions due to SARS-CoV-2 co-infection with accompanying details can be found in Appendix 2.

Additional information

Competing interests

Robert Cohen: received consulting fees from Pfizer, Sanofi, MSD, and GSK, including travel grants from Pfizer and payments from Symposium Pfizer, MSD, GSK, and Sanofi, and participated in advisory/data safety monitoring board at Pfizer, Sanofi, MSD, and GSK. Corinne Levy: received travel grants from Pfizer and payments from Symposium Pfizer and MSD. Lulla Opatowski: received a research grant from Pfizer and Sanofi Pasteur on unrelated topics through her institution. The other authors declare that no competing interests exist.

Funding

Funder	Grant reference number	Author
Agence Nationale de la Recherche	ANR-10-LABX-62 IBEID	Aleksandra Kovacevic Lulla Opatowski
Université Paris-Saclay	AAP Covid-19 2020	Lulla Opatowski
Agence Nationale de la Recherche	SPHINX-17-CE36-0008-01	Laura Temime
Fondation de France	MODCOV Grant 106059	Lulla Opatowski Laura Temime
Institut National de la Santé et de la Recherche Médicale		Lulla Opatowski
Institut Pasteur		Lulla Opatowski
Conservatoire National des Arts et Métiers		Laura Temime
Université de Versailles Saint-Quentin-en-Yvelines		Lulla Opatowski

Funder **Grant reference number** **Author**

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Aleksandra Kovacevic, Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing; David RM Smith, Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing; Eve Rahbé, Paul Henriot, Investigation, Writing – original draft, Writing – review and editing; Sophie Novelli, Investigation, Writing – original draft; Emmanuelle Varon, Robert Cohen, Corinne Levy, Writing – review and editing; Laura Temime, Conceptualization, Funding acquisition, Methodology, Writing – review and editing; Lulla Opatowski, Conceptualization, Supervision, Funding acquisition, Methodology, Writing – review and editing

Author ORCIDs

Aleksandra Kovacevic  <https://orcid.org/0000-0001-9740-6207>

Eve Rahbé  <http://orcid.org/0000-0002-3828-3910>

Laura Temime  <http://orcid.org/0000-0002-8850-5403>

Decision letter and Author response

Decision letter <https://doi.org/10.7554/eLife.85701.sa1>

Author response <https://doi.org/10.7554/eLife.85701.sa2>

Additional files**Supplementary files**

- MDAR checklist

Data availability

Source Data 1 contains the numerical data used to generate Figure 1.

References

- Abdullahi O**, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, Jomo J, Musyimi R, Lipsitch M, Scott JAG. 2012. Rates of acquisition and clearance of pneumococcal serotypes in the nasopharynx of children in Kilifi District, Kenya. *The Journal of Infectious Diseases* **206**:1020–1029. DOI: <https://doi.org/10.1093/infdis/jis447>, PMID: 22829650
- Allieta M**, Allieta A, Rossi Sebastiano D. 2022. COVID-19 outbreak in Italy: estimation of reproduction numbers over 2 months prior to phase 2. *Zeitschrift Fur Gesundheitswissenschaften = Journal of Public Health* **30**:2719–2727. DOI: <https://doi.org/10.1007/s10389-021-01567-1>, PMID: 34036037
- Alpkvist H**, Athlin S, Nauclicr P, Herrmann B, Abdeldaim G, Slotved HC, Hedlund J, Strålin K. 2015. Clinical and microbiological factors associated with high nasopharyngeal pneumococcal density in patients with pneumococcal pneumonia. *PLOS ONE* **10**:e0140112. DOI: <https://doi.org/10.1371/journal.pone.0140112>, PMID: 26466142
- Amin-Chowdhury Z**, Aiano F, Mensah A, Sheppard CL, Litt D, Fry NK, Andrews N, Ramsay ME, Ladhani SN. 2021. Impact of the coronavirus disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England. *Clinical Infectious Diseases* **72**:e65–e75. DOI: <https://doi.org/10.1093/cid/ciaa1728>, PMID: 33196783
- Andrews A**, Bou-Antoun S, Guy R, Brown CS, Hopkins S, Gerver S. 2022. Respiratory antibacterial prescribing in primary care and the COVID-19 pandemic in England, winter season 2020–21. *The Journal of Antimicrobial Chemotherapy* **77**:799–802. DOI: <https://doi.org/10.1093/jac/dkab443>, PMID: 34897486
- Arduin H**, Domenech de Cellès M, Guillemot D, Watier L, Opatowski L. 2017. An agent-based model simulation of influenza interactions at the host level: insight into the influenza-related burden of pneumococcal infections. *BMC Infectious Diseases* **17**:382. DOI: <https://doi.org/10.1186/s12879-017-2464-z>, PMID: 28577533
- Baggs J**, Jernigan JA, Halpin AL, Epstein L, Hatfield KM, McDonald LC. 2018. Risk of subsequent sepsis within 90 days after a hospital stay by type of antibiotic exposure. *Clinical Infectious Diseases* **66**:1004–1012. DOI: <https://doi.org/10.1093/cid/cix947>, PMID: 29136126
- Bara W**, Brun-Buisson C, Coignard B, Watier L. 2022. Outpatient antibiotic prescriptions in France: patients and providers characteristics and impact of the COVID-19 Pandemic. *Antibiotics* **11**:643. DOI: <https://doi.org/10.3390/antibiotics11050643>, PMID: 35625287

- Bednarčuk N**, Golić Jelić A, Stoisavljević Šatara S, Stojaković N, Marković Peković V, Stojiljković MP, Popović N, Škrbić R. 2023. Antibiotic Utilization during COVID-19: are we over-prescribing? *Antibiotics* **12**:308. DOI: <https://doi.org/10.3390/antibiotics12020308>
- Bennett JC**, Emanuels A, Heimonen J, O'Hanlon J, Hughes JP, Han PD, Chow EJ, Ogokeh CE, Rolfes MA, Lockwood CM, Pfau B, Uyeki TM, Shendure J, Hoag S, Fay K, Lee J, Sibley TR, Rogers JH, Starita LM, Englund JA, et al. 2023. *Streptococcus pneumoniae* nasal carriage patterns with and without common respiratory virus detections in households in Seattle, WA, USA before and during the COVID-19 pandemic. *Frontiers in Pediatrics* **11**:1198278. DOI: <https://doi.org/10.3389/fped.2023.1198278>, PMID: 37484765
- Bhowmick S**, Sokolov IM, Lentz HHK. 2023. Decoding the double trouble: A mathematical modelling of co-infection dynamics of SARS-CoV-2 and influenza-like illness. *Bio Systems* **224**:104827. DOI: <https://doi.org/10.1016/j.biosystems.2023.104827>, PMID: 36626949
- Bogdanić N**, Močibob L, Vidović T, Soldo A, Begovčić J. 2022. Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020. *PLOS ONE* **17**:e0263437. DOI: <https://doi.org/10.1371/journal.pone.0263437>, PMID: 35108332
- Braunstein SL**, Lazar R, Wahnich A, Daskalakis DC, Blackstock OJ. 2020. COVID-19 infection among people with HIV in New York City: a population-level analysis of matched surveillance data. *SSRN Electronic Journal* **01**:3675416. DOI: <https://doi.org/10.2139/ssrn.3675416>
- Breuggemann AB**, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, van der Linden MPG, Amin-Chowdhury Z, Bennett DE, Borrow R, Brandileone MCC, Broughton K, Campbell R, Cao B, Casanova C, Choi EH, Chu YW, Clark SA, Claus H, Coelho J, et al. 2021. Changes in the incidence of invasive disease due to *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *The Lancet. Digital Health* **3**:e360–e370. DOI: [https://doi.org/10.1016/S2589-7500\(21\)00077-7](https://doi.org/10.1016/S2589-7500(21)00077-7), PMID: 34045002
- Buehrle DJ**, Wagener MM, Nguyen MH, Clancy CJ. 2021. Trends in outpatient antibiotic prescriptions in the united states during the covid-19 pandemic in 2020. *JAMA Network Open* **4**:e2126114. DOI: <https://doi.org/10.1001/jamanetworkopen.2021.26114>, PMID: 34550387
- Cascante-Vega J**, Galanti M, Schley K, Pei S, Shaman J. 2023. Inference of transmission dynamics and retrospective forecast of invasive meningococcal disease. *PLOS Computational Biology* **19**:e1011564. DOI: <https://doi.org/10.1371/journal.pcbi.1011564>, PMID: 37889910
- Chen C**, Zhu P, Zhang Y, Liu B. 2021. Effect of the “Normalized Epidemic Prevention and Control Requirements” on hospital-acquired and community-acquired infections in China. *BMC Infectious Diseases* **21**:1178. DOI: <https://doi.org/10.1186/s12879-021-06886-y>, PMID: 34814857
- Chen Y**, Li N, Lourenço J, Wang L, Cazelles B, Dong L, Li B, Liu Y, Jit M, Bosse NI, Abbott S, Velayudhan R, Wilder-Smith A, Tian H, Brady OJ, Procter SR, Wong KL, Hellewell J, Davies NG, Jarvis CI, et al. 2022. Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. *The Lancet. Infectious Diseases* **22**:657–667. DOI: [https://doi.org/10.1016/S1473-3099\(22\)00025-1](https://doi.org/10.1016/S1473-3099(22)00025-1), PMID: 35247320
- Chien Y-C**, Lee Y-L, Liu P-Y, Lu M-C, Shao P-L, Lu P-L, Cheng S-H, Lin C-Y, Wu T-S, Yen M-Y, Wang L-S, Liu C-P, Lee W-S, Shi Z-Y, Chen Y-S, Wang F-D, Tseng S-H, Chen Y-H, Sheng W-H, Lee C-M, et al. 2021. National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive *Streptococcus pneumoniae* isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020. *Journal of Global Antimicrobial Resistance* **26**:308–316. DOI: <https://doi.org/10.1016/j.jgar.2021.07.005>
- Clancy CJ**, Buehrle DJ, Nguyen MH. 2020. PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. *JAC-Antimicrobial Resistance* **2**:dlaa049. DOI: <https://doi.org/10.1093/jacamr/dlaa049>, PMID: 34192248
- Cohen R**, Bidet P, Varon E, Béchet S, Cohen JF, Bonacorsi S, Levy C. 2023. Unprecedentedly high rates of Group A *Streptococcus* nasopharyngeal carriage in infants and toddlers in France, 2022–2023. *Infectious Diseases Now* **53**:104720. DOI: <https://doi.org/10.1016/j.idnow.2023.104720>, PMID: 37196808
- Colijn C**, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. 2010. What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of *Streptococcus pneumoniae*? *Journal of the Royal Society, Interface* **7**:905–919. DOI: <https://doi.org/10.1098/rsif.2009.0400>, PMID: 19940002
- Crisafulli S**, Ientile V, L'Abbate L, Fontana A, Linguiti C, Manna S, Mercaldo M, Pagliaro C, Vezzaro M, Santacà K, Lora R, Moretti U, Reno C, Fantini MP, Corrao S, Barbato D, Tari M, Trifirò G. 2021. COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. *Journal of Clinical Medicine* **11**:51. DOI: <https://doi.org/10.3390/jcm11010051>, PMID: 35011810
- Dagan R**, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, Cohen T, Lipsitch M, Greenberg D. 2008. Seasonality of antibiotic-resistant *Streptococcus pneumoniae* that causes acute otitis media: a clue for an antibiotic-restriction policy? *The Journal of Infectious Diseases* **197**:1094–1102. DOI: <https://doi.org/10.1086/528995>, PMID: 18419528
- Dagan R**, van der Beek BA, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger DM, Danino D. 2023. The COVID-19 pandemic as an opportunity for unravelling the causative association between respiratory viruses and pneumococcus-associated disease in young children: a prospective study. *EBioMedicine* **90**:104493. DOI: <https://doi.org/10.1016/j.ebiom.2023.104493>, PMID: 36857965

- Danion F**, Margue M, Ruch Y, Séverac F, Hansmann Y. 2023. Seasonal variation in azithromycin prescription. *The Lancet. Infectious Diseases* **23**:277–278. DOI: [https://doi.org/10.1016/S1473-3099\(23\)00009-9](https://doi.org/10.1016/S1473-3099(23)00009-9), PMID: 36736337
- D'Arienzo M**, Coniglio A. 2020. Assessment of the SARS-CoV-2 basic reproduction number, R₀, based on the early phase of COVID-19 outbreak in Italy. *Biosafety and Health* **2**:57–59. DOI: <https://doi.org/10.1016/j.bshealth.2020.03.004>
- Davies NG**, Flasche S, Jit M, Atkins KE. 2019. Within-host dynamics shape antibiotic resistance in commensal bacteria. *Nature Ecology & Evolution* **3**:440–449. DOI: <https://doi.org/10.1038/s41559-018-0786-x>, PMID: 30742105
- Diavatopoulos DA**, Short KR, Price JT, Wilksch JJ, Brown LE, Briles DE, Strugnell RA, Wijburg OL. 2010. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. *FASEB Journal* **24**:1789–1798. DOI: <https://doi.org/10.1096/fj.09-146779>, PMID: 20097876
- Di Domenico L**, Pullano G, Sabbatini CE, Boëlle P-Y, Colizza V. 2020. Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. *BMC Medicine* **18**:240. DOI: <https://doi.org/10.1186/s12916-020-01698-4>, PMID: 32727547
- Doan T**, Worden L, Hinterwirth A, Arzika AM, Maliki R, Abdou A, Zhong L, Chen C, Cook C, Lebas E, O'Brien KS, Oldenburg CE, Chow ED, Porco TC, Lipsitch M, Keenan JD, Lietman TM. 2020. Macrolide and nonmacrolide resistance with mass azithromycin distribution. *The New England Journal of Medicine* **383**:1941–1950. DOI: <https://doi.org/10.1056/NEJMoa2002606>, PMID: 33176084
- Domenech de Cellès M**, Arduin H, Lévy-Bruhl D, Georges S, Souty C, Guillemot D, Watier L, Opatowski L. 2019. Unraveling the seasonal epidemiology of pneumococcus. *PNAS* **116**:1802–1807. DOI: <https://doi.org/10.1073/pnas.1812388116>, PMID: 30642967
- Duffy E**, Thomas M, Hills T, Ritchie S. 2021. The impacts of New Zealand's COVID-19 epidemic response on community antibiotic use and hospitalisation for pneumonia, peritonsillar abscess and rheumatic fever. *The Lancet Regional Health* **12**:100162. DOI: <https://doi.org/10.1016/j.lanwpc.2021.100162>, PMID: 34124704
- Ekdahl K**, Ahlinder I, Hansson HB, Melander E, Mölsted S, Söderström M, Persson K. 1997. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. *Clinical Infectious Diseases* **25**:1113–1117. DOI: <https://doi.org/10.1086/516103>, PMID: 9402367
- Elias C**, Sekri A, Leblanc P, Cucherat M, Vanhems P. 2021. The incubation period of COVID-19: A meta-analysis. *International Journal of Infectious Diseases* **104**:708–710. DOI: <https://doi.org/10.1016/j.ijid.2021.01.069>
- European Centre for Disease Prevention and Control**, World Health Organization. 2022. *Antimicrobial Resistance Surveillance in Europe: 2022: 2020 Data*. LU: Publications Office.
- Flaxman S**, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C, Zhu H, Berah T, Eaton JW, Monod M, Ghani AC, Donnelly CA, Riley S, Vollmer MAC, Ferguson NM, Okell LC, Bhatt S, Imperial College COVID-19 Response Team. 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* **584**:257–261. DOI: <https://doi.org/10.1038/s41586-020-2405-7>, PMID: 32512579
- Foulds G**, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. *The Journal of Antimicrobial Chemotherapy* **25 Suppl A**:73–82. DOI: https://doi.org/10.1093/jac/25.suppl_a.73, PMID: 2154441
- Garcia-Vidal C**, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F, Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, et al. 2021. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clinical Microbiology and Infection* **27**:83–88. DOI: <https://doi.org/10.1016/j.cmi.2020.07.041>, PMID: 32745596
- Girard D**, Finegan SM, Dunne MW, Lame ME. 2005. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. *The Journal of Antimicrobial Chemotherapy* **56**:365–371. DOI: <https://doi.org/10.1093/jac/dki241>, PMID: 16002421
- Grant J**, Saux NL. 2021. Duration of antibiotic therapy for common infections. *Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal Officiel de l'Association Pour La Microbiologie Medicale et l'infectiologie Canada* **6**:181–197. DOI: <https://doi.org/10.3138/jammi-2021-04-29>, PMID: 36337760
- Henig O**, Kehat O, Meijer SE, Chikly A, Weiss-Meilik A, Egoz E, Ben-Ami R, Paran Y. 2021. Antibiotic Use during the COVID-19 pandemic in a tertiary hospital with an ongoing antibiotic stewardship program. *Antibiotics* **10**:1056. DOI: <https://doi.org/10.3390/antibiotics10091056>, PMID: 34572638
- Högberg LD**, Vlahović-Palčevski V, Pereira C, Weist K, Monnet DL, ESAC-Net study group, ESAC-Net study group participants. 2021. Decrease in community antibiotic consumption during the COVID-19 pandemic, EU/EEA, 2020. *Euro Surveillance* **26**:2101020. DOI: <https://doi.org/10.2807/1560-7917.ES.2021.26.46.2101020>, PMID: 34794534
- Homeniuk R**, Collins C. 2021. How COVID-19 has affected general practice consultations and income: general practitioner cross-sectional population survey evidence from Ireland. *BMJ Open* **11**:e044685. DOI: <https://doi.org/10.1136/bmjopen-2020-044685>
- Hsu J**. 2020. How covid-19 is accelerating the threat of antimicrobial resistance. *BMJ* **369**:m1983. DOI: <https://doi.org/10.1136/bmj.m1983>, PMID: 32423901
- Hussain AZ**, Paudyal V, Hadi MA. 2021. Impact of the COVID-19 Pandemic on the Prescribing Patterns of First-Line Antibiotics in English Primary Care: A Longitudinal Analysis of National Prescribing Dataset. *Antibiotics* **10**:591. DOI: <https://doi.org/10.3390/antibiotics10050591>, PMID: 34067546

- Jenness SM**, Le Guillou A, Chandra C, Mann LM, Sanchez T, Westreich D, Marcus JL. 2021. Projected HIV and bacterial sexually transmitted infection incidence following COVID-19-related sexual distancing and clinical service interruption. *The Journal of Infectious Diseases* **223**:1019–1028. DOI: <https://doi.org/10.1093/infdis/jiab051>, PMID: 33507308
- Kadambari S**, Goldacre R, Morris E, Goldacre MJ, Pollard AJ. 2022. Indirect effects of the covid-19 pandemic on childhood infection in England: population based observational study. *BMJ* **376**:e067519. DOI: <https://doi.org/10.1136/bmj-2021-067519>, PMID: 35022215
- Karami Z**, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, Kerckhoffs APM, van de Maat JS, Hoogerwerf JJ, ten Oever J. 2021. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. *Infectious Diseases* **53**:102–110. DOI: <https://doi.org/10.1080/23744235.2020.1839672>
- Keenan JD**, Klugman KP, McGee L, Vidal JE, Chochua S, Hawkins P, Cevallos V, Gebre T, Tadesse Z, Emerson PM, Jorgensen JH, Gaynor BD, Lietman TM. 2015. Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments. *The Journal of Infectious Diseases* **211**:988–994. DOI: <https://doi.org/10.1093/infdis/jiu552>, PMID: 25293366
- Keenan JD**, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Leitman TM. 2018. Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa. *The New England Journal of Medicine* **378**:1583–1592. DOI: <https://doi.org/10.1056/NEJMoa1715474>
- Khouja T**, Mitsantisuk K, Tadrous M, Suda KJ. 2022. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). *Journal of Antimicrobial Chemotherapy* **77**:1491–1499. DOI: <https://doi.org/10.1093/jac/dkac028>
- Knight GM**, Glover RE, McQuaid CF, Oлару ID, Gallandat K, Leclerc QJ, Fuller NM, Willcocks SJ, Hasan R, van Kleef E, Chandler CI. 2021. Antimicrobial resistance and COVID-19: Intersections and implications. *eLife* **10**:e64139. DOI: <https://doi.org/10.7554/eLife.64139>, PMID: 33588991
- Kournoutou GG**, Dinos G. 2022. Azithromycin through the Lens of the COVID-19 Treatment. *Antibiotics* **11**:1063. DOI: <https://doi.org/10.3390/antibiotics11081063>, PMID: 36009932
- Kovacevic A**. 2024. antibiotic_resistance. sw-h:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996. Software Heritage. https://archive.softwareheritage.org/sw-h:1:dir:db75008f81b8b1494e623f024b566ddc0e59e4a0;origin=https://github.com/alekskovacevic/antibiotic_resistance;visit=sw-h:1:snp:3399afe72a09fca6904c379bf83475ddb356c27e;anchor=sw-h:1:rev:2e1a778298d23145d46d8d3f702a21ec16e57996
- Kuitunen I**, Jääskeläinen J, Korppi M, Renko M. 2023. Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries—a systematic review and meta-analysis. *Clinical Infectious Diseases* **76**:e1123–e1128. DOI: <https://doi.org/10.1093/cid/ciac374>, PMID: 35579504
- Langford BJ**, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JPR, Daneman N. 2020. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical Microbiology and Infection* **26**:1622–1629. DOI: <https://doi.org/10.1016/j.cmi.2020.07.016>, PMID: 32711058
- Langford BJ**, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, Daneman N, MacFadden DR. 2021. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clinical Microbiology and Infection* **27**:520–531. DOI: <https://doi.org/10.1016/j.cmi.2020.12.018>, PMID: 33418017
- Lauer SA**, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. 2020. The Incubation Period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Annals of Internal Medicine* **172**:577–582. DOI: <https://doi.org/10.7326/M20-0504>, PMID: 32150748
- Lehtinen S**, Blanquart F, Croucher NJ, Turner P, Lipsitch M, Fraser C. 2017. Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. *PNAS* **114**:1075–1080. DOI: <https://doi.org/10.1073/pnas.1617849114>, PMID: 28096340
- Lipsitch M**, Colijn C, Cohen T, Hanage WP, Fraser C. 2009. No coexistence for free: neutral null models for multistrain pathogens. *Epidemics* **1**:2–13. DOI: <https://doi.org/10.1016/j.epidem.2008.07.001>, PMID: 21352747
- Liu Y**, Gayle AA, Wilder-Smith A, Rocklöv J. 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *Journal of Travel Medicine* **27**:021. DOI: <https://doi.org/10.1093/jtm/taaa021>
- Malhotra-Kumar S**, Lammens C, Coenen S, Van Herck K, Goossens H. 2007. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *The Lancet* **369**:482–490. DOI: [https://doi.org/10.1016/S0140-6736\(07\)60235-9](https://doi.org/10.1016/S0140-6736(07)60235-9)
- Mamun AA**, Saatchi A, Xie M, Lishman H, Blondel-Hill E, Marra F, Patrick DM. 2021. Community antibiotic use at the population level during the SARS-CoV-2 Pandemic in British Columbia, Canada. *Open Forum Infectious Diseases* **8**:ofab185. DOI: <https://doi.org/10.1093/ofid/ofab185>, PMID: 34183981
- McCullers JA**, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. 2010. Influenza enhances susceptibility to natural acquisition of and disease due to *Streptococcus pneumoniae* in ferrets. *The Journal of Infectious Diseases* **202**:1287–1295. DOI: <https://doi.org/10.1086/656333>, PMID: 20822454
- Melegaro A**, Gay NJ, Medley GF. 2004. Estimating the transmission parameters of pneumococcal carriage in households. *Epidemiology and Infection* **132**:433–441. DOI: <https://doi.org/10.1017/s0950268804001980>, PMID: 15188713

- Melnyk AH**, Wong A, Kassen R. 2015. The fitness costs of antibiotic resistance mutations. *Evolutionary Applications* **8**:273–283. DOI: <https://doi.org/10.1111/eva.12196>, PMID: 25861385
- Monnet DL**, Harbarth S. 2020. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? *Euro Surveill* **25**:2001886. DOI: <https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001886>, PMID: 33183403
- Mulberry N**, Rutherford A, Colijn C. 2020. Systematic comparison of coexistence in models of drug-sensitive and drug-resistant pathogen strains. *Theoretical Population Biology* **133**:150–158. DOI: <https://doi.org/10.1016/j.tpb.2019.12.001>, PMID: 31887315
- Murray CJL**, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, Kashef Hamadani BH, Kumaran EAP, McManigal B, Achalapong S, et al. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* **399**:629–655. DOI: [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Nandi A**, Pecetta S, Bloom DE. 2023. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022. *eClinicalMedicine* **57**:101848. DOI: <https://doi.org/10.1016/j.eclinm.2023.101848>
- Nation ML**, Manna S, Tran HP, Nguyen CD, Vy LTT, Uyen DY, Phuong TL, Dai VTT, Ortika BD, Wee-Hee AC, Beissbarth J, Hinds J, Bright K, Smith-Vaughan H, Nguyen TV, Mulholland K, Temple B, Satzke C. 2023. Impact of COVID-19 Nonpharmaceutical Interventions on Pneumococcal Carriage Prevalence and Density in Vietnam. *Microbiology Spectrum* **11**:e0361522. DOI: <https://doi.org/10.1128/spectrum.03615-22>, PMID: 36645282
- Olesen SW**, Lipsitch M, Grad YH. 2020. The role of “spillover” in antibiotic resistance. *PNAS* **117**:29063–29068. DOI: <https://doi.org/10.1073/pnas.2013694117>, PMID: 33139558
- Olwagen CP**, Downs SL, Izu A, Tharasimbi L, Van Der Merwe L, Nunes MC, Madhi SA. 2024. Bacterial nasopharyngeal colonisation in children in South Africa before and during the COVID-19 pandemic: an observational study. *The Lancet. Microbe* **5**:e34–e42. DOI: [https://doi.org/10.1016/S2666-5247\(23\)00260-4](https://doi.org/10.1016/S2666-5247(23)00260-4), PMID: 38048806
- Opatowski L**, Varon E, Dupont C, Temime L, van der Werf S, Gutmann L, Boëlle P-Y, Watier L, Guilletot D. 2013. Assessing pneumococcal meningitis association with viral respiratory infections and antibiotics: insights from statistical and mathematical models. *Proceedings of the Royal Society B* **280**:20130519. DOI: <https://doi.org/10.1098/rspb.2013.0519>
- Palmer K**, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, Prieto R, Sykara G, Donde S. 2020. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing. *Aging Clinical and Experimental Research* **32**:1189–1194. DOI: <https://doi.org/10.1007/s40520-020-01601-4>
- Parveen M**, Molla MMA, Yeasmin M, Nafisa T, Barna AA, Ghosh AK. 2020. Evidences on Irrational anti-microbial prescribing and consumption among COVID-19 positive patients and possible mitigation strategies: a descriptive cross sectional study. *Bangladesh Journal of Infectious Diseases* **7**:S3–S7. DOI: <https://doi.org/10.3329/bjid.v7i00.50155>
- Petrović V**, Milosavljević B, Djilas M, Marković M, Vuković V, Andrijević I, Ristić M. 2022. Pneumococcal nasopharyngeal carriage in children under 5 years of age at an outpatient healthcare facility in Novi Sad, Serbia during the COVID-19 pandemic. *IJID Regions* **4**:88–96. DOI: <https://doi.org/10.1016/j.ijregi.2022.07.001>, PMID: 35865274
- PRINCIPLE Trial Collaborative Group**. 2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet* **397**:1063–1074. DOI: [https://doi.org/10.1016/S0140-6736\(21\)00461-X](https://doi.org/10.1016/S0140-6736(21)00461-X), PMID: 33676597
- Read B**, McLeod M, Tonkin-Crine S, Ashiru-Oredope D, Quigley A, Brown CS, Lecky DM. 2023. Changes in public health-seeking behaviours for self-limiting respiratory tract infections across England during the COVID-19 pandemic. *European Journal of Public Health* **33**:987–993. DOI: <https://doi.org/10.1093/eurpub/ckad136>, PMID: 37561411
- Rebello JS**, Domingues CPF, Dionisio F, Gomes MC, Botelho A, Nogueira T. 2021. COVID-19 lockdowns may reduce resistance genes diversity in the human microbiome and the need for antibiotics. *International Journal of Molecular Sciences* **22**:6891. DOI: <https://doi.org/10.3390/ijms22136891>, PMID: 34206965
- Rhee C**, Baker M, Vaidya V, Tucker R, Resnick A, Morris CA, Klompas M, CDC Prevention Epicenters Program. 2020. Incidence of Nosocomial COVID-19 in patients hospitalized at a large us academic medical center. *JAMA Network Open* **3**:e2020498. DOI: <https://doi.org/10.1001/jamanetworkopen.2020.20498>, PMID: 32902653
- Rose MA**, Laurenz M, Sprenger R, Imöhl M, van der Linden M. 2021. nasopharyngeal carriage in children after the introduction of generalized infant pneumococcal conjugate vaccine immunization in Germany. *Frontiers in Medicine* **8**:719481. DOI: <https://doi.org/10.3389/fmed.2021.719481>
- Roux J**, Massonnaud C, Crépey P. 2020. COVID-19: One-Month Impact of the French Lockdown on the Epidemic Burden. *bioRxiv*. DOI: <https://doi.org/10.1101/2020.04.22.20075705>
- Rusic D**, Vilovic M, Bukic J, Leskur D, Seselja Perisin A, Kumric M, Martinovic D, Petric A, Modun D, Bozic J. 2021. Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks. *Life* **11**:220. DOI: <https://doi.org/10.3390/life11030220>, PMID: 33801799
- Rybak A**, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, Vaux S, Levy-Bruhl D, van der Werf S, Béchet S, Bonacorsi S, Assad Z, Lazzati A, Michel M, Kaguelidou F, Faye A, Cohen R, Varon E, Ouldali N. 2022. association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal

- disease, pneumococcal carriage, and respiratory viral Infections among children in france. *JAMA Network Open* **5**:e2218959. DOI: <https://doi.org/10.1001/jamanetworkopen.2022.18959>, PMID: 35763298
- Ryu S, Hwang Y, Ali ST, Kim DS, Klein EY, Lau EHY, Cowling BJ. 2021. Decreased use of broad-spectrum antibiotics during the coronavirus disease 2019 epidemic in South Korea. *The Journal of Infectious Diseases* **224**:949–955. DOI: <https://doi.org/10.1093/infdis/jiab208>, PMID: 33856455
- Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, Andronico A, Hozé N, Richet J, Dubost CL, Le Strat Y, Lessler J, Levy-Bruhl D, Fontanet A, Opatowski L, Boelle PY, Cauchemez S. 2020. Estimating the burden of SARS-CoV-2 in France. *Science* **369**:208–211. DOI: <https://doi.org/10.1126/science.abc3517>, PMID: 32404476
- Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, Griffith D, Jeffreys D, Hamilton K, Choo-Kang B, Brittain S, Guthrie D, Sneddon J. 2020. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. *The Journal of Infection* **81**:952–960. DOI: <https://doi.org/10.1016/j.jinf.2020.09.024>, PMID: 32987097
- Sender V, Hentrich K, Henriques-Normark B. 2021. virus-induced changes of the respiratory tract environment promote secondary infections with *Streptococcus pneumoniae* *Frontiers in Cellular and Infection Microbiology* **11**:643326. DOI: <https://doi.org/10.3389/fcimb.2021.643326>, PMID: 33828999
- Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Cao B, Casanova C, Choi EH, Chu Y-W, Claus H, Coelho J, Corcoran M, Cottrell S, Cunney R, Cuypers L, Dalby T, Davies H, de Gouveia L, Deghmane A-E, et al. 2023. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. *The Lancet Digital Health* **5**:e582–e593. DOI: [https://doi.org/10.1016/S2589-7500\(23\)00108-5](https://doi.org/10.1016/S2589-7500(23)00108-5)
- Short KR, Reading PC, Wang N, Diavatopoulos DA, Wijburg OL. 2012. Increased nasopharyngeal bacterial titers and local inflammation facilitate transmission of *Streptococcus pneumoniae*. *mBio* **3**:e00255-12. DOI: <https://doi.org/10.1128/mBio.00255-12>, PMID: 23015738
- Shrestha S, Foxman B, Dawid S, Aiello AE, Davis BM, Berus J, Rohani P. 2013. Time and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and *Streptococcus pneumoniae*. *Journal of The Royal Society Interface* **10**:20130233. DOI: <https://doi.org/10.1098/rsif.2013.0233>
- Smith DRM, Opatowski L. 2021. COVID-19 containment measures and incidence of invasive bacterial disease. *The Lancet. Digital Health* **3**:e331–e332. DOI: [https://doi.org/10.1016/S2589-7500\(21\)00085-6](https://doi.org/10.1016/S2589-7500(21)00085-6), PMID: 34044998
- Smith DRM, Shirreff G, Temime L, Opatowski L. 2023. Collateral impacts of pandemic COVID-19 drive the nosocomial spread of antibiotic resistance: A modelling study. *PLOS Medicine* **20**:e1004240. DOI: <https://doi.org/10.1371/journal.pmed.1004240>, PMID: 37276186
- Soetaert K, Petzoldt T, Setzer RW. 2010. Solving differential equations in R: package deSolve. *Journal of Statistical Software* **33**:1–25. DOI: <https://doi.org/10.18637/jss.v033.i09>
- Teng JLL, Fok KMN, Lin KPK, Chan E, Ma Y, Lau SKP, Woo PCY. 2022. Substantial decline in invasive pneumococcal disease during coronavirus disease 2019 pandemic in Hong Kong. *Clinical Infectious Diseases* **74**:335–338. DOI: <https://doi.org/10.1093/cid/ciab382>
- Tinggaard M, Slotved HC, Petersen RF, Hovmand N, Benfield T. 2023. Decreased Pneumococcal carriage among older adults in denmark during the COVID-19 Lockdown. *Open Forum Infectious Diseases* **10**:ofad365. DOI: <https://doi.org/10.1093/ofid/ofad365>, PMID: 37559754
- Tsay SV, Bartoces M, Gouin K, Kabbani S, Hicks LA. 2022. Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021. *JAMA* **327**:2018–2019. DOI: <https://doi.org/10.1001/jama.2022.5471>, PMID: 35394497
- Van Laethem J, Wuyts S, Van Laere S, Dirckx S, Seyler L, Mertens R, Ilsen B, Lacor P, Pierard D, Allard SD. 2021. Antibiotic Prescriptions Targeting Bacterial Respiratory Infections in Admitted Patients with COVID-19: A Prospective Observational Study. *Infectious Diseases and Therapy* **10**:2575–2591. DOI: <https://doi.org/10.1007/s40121-021-00535-2>, PMID: 34529255
- Wang L, Fu J, Liang Z, Chen J. 2017. Prevalence and serotype distribution of nasopharyngeal carriage of *Streptococcus pneumoniae* in China: a meta-analysis. *BMC Infectious Diseases* **17**:765. DOI: <https://doi.org/10.1186/s12879-017-2816-8>, PMID: 29237402
- Weill A, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Zureik M. 2021. *Usage Des Médicaments de Ville En France Durant L'Épidémie de La COVID-19 – Point de Situation Jusqu'au 25 Avril 2021. Étude Pharmaco-Épidémiologique à Partir Des Données de Remboursement Du SNDS*. EPI-PHARE (Groupement d'intérêt scientifique ANSM-Cnam).
- Willen L, Ekinci E, Cuypers L, Theeten H, Desmet S. 2021. Infant pneumococcal carriage in belgium not affected by COVID-19 containment measures. *Frontiers in Cellular and Infection Microbiology* **11**:825427. DOI: <https://doi.org/10.3389/fcimb.2021.825427>, PMID: 35111700
- Wittman SR, Martin JM, Mehrotra A, Ray KN. 2023. Antibiotic Receipt During Outpatient Visits for COVID-19 in the US, From 2020 to 2022. *JAMA Health Forum* **4**:e225429. DOI: <https://doi.org/10.1001/jamahealthforum.2022.5429>, PMID: 36800196
- Wolter N, Tempia S, Cohen C, Madhi SA, Venter M, Moyes J, Walaza S, Malope-Kgokong B, Groome M, du Plessis M, Magomani V, Pretorius M, Hellferscee O, Dawood H, Kahn K, Variava E, Klugman KP, von Gottberg A. 2014. High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. *The Journal of Infectious Diseases* **210**:1649–1657. DOI: <https://doi.org/10.1093/infdis/jiu326>, PMID: 24907383

- Wong A**, Barrero Guevara LA, Goult E, Briga M, Kramer SC, Kovacevic A, Opatowski L, Domenech de Cellès M. 2023. The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps. *PLOS Pathogens* **19**:e1011167. DOI: <https://doi.org/10.1371/journal.ppat.1011167>, PMID: [36888684](https://pubmed.ncbi.nlm.nih.gov/36888684/)
- Wyllie AL**, Mbodj S, Thammavongsa DA, Hislop MS, Yolda-Carr D, Waghela P, Nakahata M, Stahlfeld AE, Vega NJ, York A, Allicock OM, Wilkins G, Ouyang A, Siqueiros L, Strong Y, Anastasio K, Alexander-Parrish R, Arguedas A, Gessner BD, Weinberger DM. 2023. Persistence of Pneumococcal carriage among older adults in the community despite COVID-19 mitigation measures. *Microbiology Spectrum* **11**:e0487922. DOI: <https://doi.org/10.1128/spectrum.04879-22>, PMID: [37036377](https://pubmed.ncbi.nlm.nih.gov/37036377/)
- Zhang T**, Shen X, Liu R, Zhao L, Wang D, Lambert H, Cabral C. 2021. The impact of COVID-19 on primary health care and antibiotic prescribing in rural China: qualitative study. *BMC Health Services Research* **21**:1048. DOI: <https://doi.org/10.1186/s12913-021-07082-z>, PMID: [34610843](https://pubmed.ncbi.nlm.nih.gov/34610843/)
- Zhou C**, Jiang Y, Sun L, Li H, Liu X, Huang L. 2023. Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China. *Frontiers in Microbiology* **14**:1280026. DOI: <https://doi.org/10.3389/fmicb.2023.1280026>, PMID: [37901822](https://pubmed.ncbi.nlm.nih.gov/37901822/)
- Zhu N**, Aylin P, Rawson T, Gilchrist M, Majeed A, Holmes A. 2021. Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves. *Clinical Microbiology and Infection* **27**:762–768. DOI: <https://doi.org/10.1016/j.cmi.2021.02.007>, PMID: [33601010](https://pubmed.ncbi.nlm.nih.gov/33601010/)

Appendix 1

Literature search

We searched PubMed on December 4, 2023, for published mathematical modeling studies describing coinfection with SARS-CoV-2 and antibiotic-resistant bacteria and including epidemiological transmission of both pathogens. We used the following search query:

```
("model*[Title/Abstract] OR "models, theoretical"[MeSH Terms] OR "simulat*[Title/Abstract])
AND
("mathematic*[MeSH Terms] OR "compartmental"[Title/Abstract] OR "agent-based"[Title/Abstract] OR "individual-based"[Title/Abstract] OR "stochastic*[Title/Abstract] OR "deterministic"[Title/Abstract] OR "computer-generated"[Title/Abstract] OR "computer simulation"[MeSH Terms] OR "computer"[Title/Abstract] OR "computational"[Title/Abstract] OR "mathematical*[Title/Abstract] OR "theoretical"[Title/Abstract] OR "prediction"[Title/Abstract] OR "simulat*[Title/Abstract])
AND
("outbreak*[Title/Abstract] OR "dynamic*[Title/Abstract] OR "disseminat*[Title/Abstract] OR "propagat*[Title/Abstract] OR "transmi*[Title/Abstract] OR "cross infection/transmission"[MeSH Terms] OR "spread*[Title/Abstract] OR "diffus*[Title/Abstract] OR "circulati*[Title/Abstract] OR "disease activity"[Title/Abstract] OR "epidemiology"[Title/Abstract] OR "co-infection"[Title/Abstract])
("COVID-19"[Title/Abstract] OR "SARS-CoV-2"[Title/Abstract])
("bacteria*[Title/Abstract] OR "antibiotic resist*[Title/Abstract] OR "antibiotic-resist*[Title/Abstract] OR "antimicrobial resist*[Title/Abstract] OR "antimicrobial-resist*[Title/Abstract]),
```

which returned 153 papers. One published study developed a mathematical model including the transmission of both SARS-CoV-2 and antibiotic-resistant bacteria but is specific to the hospital setting (*Smith et al., 2023*). Two bacterial transmission models implicitly accounted for COVID-19 by simulating pandemic-associated social distancing interventions/lockdowns, and corresponding reductions in (i) close-proximity contacts, in the context of transmission of antibiotic-resistance genes among human microbiota (*Rebello et al., 2021*), and (ii) sexual contacts, in the context of transmission of HIV, gonorrhoea and chlamydia (*Jenness et al., 2021*). A third model of *Neisseria meningitidis* transmission also evaluated colonization and infection dynamics over the pandemic period (*Cascante-Vega et al., 2023*). However, none of these models included SARS-CoV-2 infection and transmission, and only the first considered antibiotic resistance. One further transmission modelling study included coinfection with SARS-CoV-2 and influenza-like illness but did not consider bacteria (*Bhowmick et al., 2023*). Our search also returned some statistical models used to analyze epidemiological trends in bacterial coinfection subsequent to SARS-CoV-2 infection (*Zhou et al., 2023*) and changes in the incidence of bacterial disease during the pandemic (*Shaw et al., 2023*), but these did not use transmission modelling approaches to understand or quantify the underlying epidemiological mechanisms driving these trends. Several other modelling studies have described within-host molecular dynamics or airborne fluid particle dynamics, but do not describe pathogen transmission at the host population level. No other relevant articles were identified.

Appendix 2

Model equations:

Compartment notation:

$$X_j^i$$

X=SARS-CoV-2 status (S=susceptible, E=exposed, I=infected, and R=recovered)

i=bacterial carriage (no superscript =no carriage, S=antibiotic-sensitive carriage, R=antibiotic-resistant carriage, SR =dual carriage, SS =dual antibiotic-sensitive carriage, RR =dual antibiotic-resistant carriage)

j=antibiotic exposure (no subscript =no antibiotic exposure, a=exposed to baseline antibiotic treatment, az =exposed to azithromycin treatment)

Total population size:

$$N = S + S^S + S^R + S^{SR} + S^{SS} + S^{RR} + S_a + S_a^S + S_a^R + S_a^{SR} + S_a^{SS} + S_a^{RR} + E + E^S + E^R + E^{SR} + E^{SS} + E^{RR} + E_a + E_a^S + E_a^R + E_a^{SR} + E_a^{SS} + E_a^{RR} + I + I^S + I^R + I^{SR} + I^{SS} + I^{RR} + I_a + I_a^S + I_a^R + I_a^{SR} + I_a^{SS} + I_a^{RR} + I_{az} + I_{az}^S + I_{az}^R + I_{az}^{SR} + I_{az}^{SS} + I_{az}^{RR} + R + R^S + R^R + R^{SR} + R^{SS} + R^{RR} + R_a + R_a^S + R_a^R + R_a^{SR} + R_a^{SS} + R_a^{RR} + I_a^{RR} + R_{az} + R_{az}^S + R_{az}^R + R_{az}^{SR} + R_{az}^{SS} + R_{az}^{RR}$$

Forces of infection:

S. pneumoniae

$$\lambda_S = \beta_S \theta_\beta \left(S^S + 2qp_s S^{SR} + 2qS^{SS} + S_a^S + 2qp_s S_a^{SR} + 2qS_a^{SS} + E^S + 2qp_s E^{SR} + 2qE^{SS} + E_a^S + 2qp_s E_a^{SR} + 2qE_a^{SS} + I^S + 2qp_s I^{SR} + 2qI^{SS} + I_a^S + 2qp_s I_a^{SR} + 2qI_a^{SS} + I_{az}^S + 2qp_s I_{az}^{SR} + 2qI_{az}^{SS} + R^S + 2qp_s R^{SR} + 2qR^{SS} + R_a^S + 2qp_s R_a^{SR} + 2qR_a^{SS} + R_{az}^S + 2qp_s R_{az}^{SR} + 2qR_{az}^{SS} \right) / N$$

$$\lambda_R = \beta_S f \theta_\beta \left(S^R + 2q(1-p_s) S^{SR} + 2qS^{RR} + S_a^R + 2q(1-p_s) S_a^{SR} + 2qS_a^{RR} + E^R + 2q(1-p_s) E^{SR} + 2qE^{RR} + E_a^R + 2q(1-p_s) E_a^{SR} + 2qE_a^{RR} + I^R + 2q(1-p_s) I^{SR} + 2qI^{RR} + I_a^R + 2q(1-p_s) I_a^{SR} + 2qI_a^{RR} + I_{az}^R + 2q(1-p_s) I_{az}^{SR} + 2qI_{az}^{RR} + R^R + 2q(1-p_s) R^{SR} + 2qR^{RR} + R_a^R + 2q(1-p_s) R_a^{SR} + 2qR_a^{RR} + R_{az}^R + 2q(1-p_s) R_{az}^{SR} + 2qR_{az}^{RR} \right) / N$$

$$\lambda_{XS} = \beta_S \theta_\beta \left(S^S + p_{single} \left(2qp_s S^{SR} + 2qS^{SS} \right) + S_a^S + p_{single} \left(2qp_s S_a^{SR} + 2qS_a^{SS} \right) + E^S + p_{single} \left(2qp_s E^{SR} + 2qE^{SS} \right) + E_a^S + p_{single} \left(2qp_s E_a^{SR} + 2qE_a^{SS} \right) + I^S + p_{single} \left(2qp_s I^{SR} + 2qI^{SS} \right) + I_a^S + p_{single} \left(2qp_s I_a^{SR} + 2qI_a^{SS} \right) + I_{az}^S + p_{single} \left(2qp_s I_{az}^{SR} + 2qI_{az}^{SS} \right) + R^S + p_{single} \left(2qp_s R^{SR} + 2qR^{SS} \right) + R_a^S + p_{single} \left(2qp_s R_a^{SR} + 2qR_a^{SS} \right) + R_{az}^S + p_{single} \left(2qp_s R_{az}^{SR} + 2qR_{az}^{SS} \right) \right) / N$$

$$\begin{aligned} \lambda_{XR} = & \beta_S f \theta_\beta \left(S^R + p_{single} \left(2q(1-p_s) S^{SR} + 2q S^{RR} \right) + S_a^R \right) \\ & + p_{single} \left(2q(1-p_s) S_a^{SR} + 2q S_a^{RR} \right) + E^R + p_{single} \left(2q(1-p_s) E^{SR} + 2q E^{RR} \right) \\ & + E_a^R + p_{single} \left(2q(1-p_s) E_a^{SR} + 2q E_a^{RR} \right) + I^R \\ & + p_{single} \left(2q(1-p_s) I^{SR} + 2q I^{RR} \right) + I_a^R + p_{single} \left(2q(1-p_s) I_a^{SR} + 2q I_a^{RR} \right) \\ & + I_{az}^R + p_{single} \left(2q(1-p_s) I_{az}^{SR} + 2q I_{az}^{RR} \right) + R^R \\ & + p_{single} \left(2q(1-p_s) R^{SR} + 2q R^{RR} \right) + R_a^R + p_{single} \left(2q(1-p_s) R_a^{SR} + 2q R_a^{RR} \right) \\ & + R_{az}^R + p_{single} \left(2q(1-p_s) R_{az}^{SR} + 2q R_{az}^{RR} \right) / N \end{aligned}$$

$$\lambda_{XSR} = \left((1 - p_{single}) (\beta_S \theta_\beta p_s + \beta_S \theta_\beta f (1 - p_s)) 2q \left(S^{SR} + S_a^{SR} + E^{SR} + E_a^{SR} \right. \right. \\ \left. \left. + I^{SR} + I_a^{SR} + I_{az}^{SR} + R^{SR} + R_a^{SR} + R_{az}^{SR} \right) / N \right)$$

$$\lambda_{XSS} = \left((1 - p_{single}) \beta_S \theta_\beta 2q \left(S^{SS} + S_a^{SS} + E^{SS} + E_a^{SS} + I^{SS} + I_a^{SS} \right. \right. \\ \left. \left. + I_{az}^{SS} + R^{SS} + R_a^{SS} + R_{az}^{SS} \right) / N \right)$$

$$\lambda_{XRR} = \left((1 - p_{single}) \beta_S \theta_\beta f 2q \left(S^{RR} + S_a^{RR} + E^{RR} + E_a^{RR} + I^{RR} + I_a^{RR} \right. \right. \\ \left. \left. + I_{az}^{RR} + R^{RR} + R_a^{RR} + R_{az}^{RR} \right) / N \right)$$

SARS-CoV-2:

$$\lambda_C = \beta_C \theta_c \left((I + I^S + I^R + I^{SR} + I^{SS} + I^{RR} + I_a + I_a^S + I_a^R + I_a^{SR} + I_a^{SS} + I_a^{RR}) \right. \\ \left. + I_{az} + I_{az}^S + I_{az}^R + I_{az}^{SR} + I_{az}^{SS} + I_{az}^{RR} \right) / N$$

Clearance rates of pneumococcal carriage:

$$\gamma^S = \gamma^R = \gamma^{SS} = \gamma^{RR} = \gamma^{SR}$$

The equations for SARS-CoV-2 susceptible individuals (no antibiotic treatment):

$$\frac{dS}{dt} = -(\lambda_{XS} + \lambda_{XR} + \lambda_{XSR} + \lambda_{XSS} + \lambda_{XRR}) S + \gamma^S (S^S + S^{SS}) + \gamma^R (S^R + S^{SR} + S^{RR} + S_a^R + S_a^{RR}) \\ + (\gamma^S + \omega) (S_a^S + S_a^{SS}) - \tau a S + r S_a - \lambda_C S$$

$$\frac{dS^S}{dt} = \lambda_{XS} S - \gamma^S S^S - k \lambda_S S^S - k \lambda_R S^S - \tau a S^S - \lambda_C S^S$$

$$\frac{dS^R}{dt} = \lambda_{XR} S - \gamma^R S^R - k \lambda_S S^R - k \lambda_R S^R - \tau a S^R + r S_a^R + (\gamma^S + \omega) S_a^{SR} - \lambda_C S^R$$

$$\frac{dS^{SR}}{dt} = \lambda_{XSR} S - \gamma^R S^{SR} + k \lambda_R S^S + k \lambda_S S^R - k c \lambda_S S^{SR} - k c \lambda_R S^{SR} + 2k c \\ \lambda_R S^{SS} + 2k c \lambda_S S^{RR} - \tau a S^{SR} - \lambda_C S^{SR}$$

$$\frac{dS^{SS}}{dt} = \lambda_{XSS} S - \gamma^S S^{SS} + k \lambda_S S^S + k c \lambda_S S^{SR} - 2k c \lambda_R S^{SS} - \tau a S^{SS} - \lambda_C S^{SS}$$

$$\frac{dS^{RR}}{dt} = \lambda_{XRR} S - \gamma^R S^{RR} + k \lambda_R S^R + k c \lambda_R S^{SR} - 2k c \lambda_S S^{RR} - \tau a S^{RR} + r S_a^{RR} - \lambda_C S^{RR}$$

The equations for SARS-CoV-2 susceptible individuals (with antibiotic treatment):

$$\begin{aligned} \frac{dS_a}{dt} &= -(\lambda_{XR} + \lambda_{XRR}) S_a + \tau a S - r S_a - \lambda_C S_a \\ \frac{dS_a^S}{dt} &= -(\gamma^S + \omega) S_a^S + \tau a S^S - k \lambda_R S_a^S - \lambda_C S_a^S \\ \frac{dS_a^R}{dt} &= -\gamma^R S_a^R + \lambda_{XR} S_a + \tau a S^R - r S_a^R - \lambda_C S_a^R \\ \frac{dS_a^{SR}}{dt} &= -(\gamma^S + \omega) S_a^{SR} + k \lambda_R S_a^S + 2kc \lambda_R S_a^{SS} + \tau a S^{SR} - \lambda_C S_a^{SR} \\ \frac{dS_a^{SS}}{dt} &= -(\gamma^S + \omega) S_a^{SS} - 2kc \lambda_R S_a^{SS} + \tau a S^{SS} - \lambda_C S_a^{SS} \\ \frac{dS_a^{RR}}{dt} &= \lambda_{XRR} S_a + \tau a S^{RR} - r S_a^{RR} - \gamma^R S_a^{RR} - \lambda_C S_a^{RR} \end{aligned}$$

The equations for SARS-CoV-2 exposed individuals (no antibiotic treatment):

$$\begin{aligned} \frac{dE}{dt} &= -(\lambda_{XS} + \lambda_{XR} + \lambda_{XSR} + \lambda_{XSS} + \lambda_{XRR}) E + \gamma^S (E^S + E^{SS}) + \gamma^R (E^R + E^{SR} + E^{RR} + E_a^R + E_a^{RR}) \\ &\quad + (\gamma^S + \omega) (E_a^S + E_a^{SS}) - \tau a E + r E_a + \lambda_C S - \varepsilon E \\ \frac{dE^S}{dt} &= \lambda_{XS} E - \gamma^S E^S - k \lambda_S E^S - k \lambda_R E^S - \tau a E^S + \lambda_C S^S - \varepsilon E^S \\ \frac{dE^R}{dt} &= \lambda_{XR} E - \gamma^R E^R - k \lambda_S E^R - k \lambda_R E^R - \tau a E^R + r E_a^R + \lambda_C S^R - \varepsilon E^R + (\gamma^S + \omega) E_a^{SR} \\ \frac{dE^{SR}}{dt} &= \lambda_{XSR} E - \gamma^R E^{SR} + k \lambda_R E^S + k \lambda_S E^R - kc \lambda_S E^{SR} - kc \lambda_R E^{SR} + 2kc \lambda_R E^{SS} + 2kc \lambda_S E^{RR} \\ &\quad - \tau a E^{SR} + \lambda_C S^{SR} - \varepsilon E^{SR} \\ \frac{dE^{SS}}{dt} &= \lambda_{XSS} E - \gamma^S E^{SS} + k \lambda_S E^S + kc \lambda_S E^{SR} - 2kc \lambda_R E^{SS} - \tau a E^{SS} + \lambda_C S^{SS} - \varepsilon E^{SS} \\ \frac{dE^{RR}}{dt} &= \lambda_{XRR} E - \gamma^R E^{RR} + k \lambda_R E^R + kc \lambda_R E^{SR} - 2kc \lambda_S E^{RR} - \tau a E^{RR} + r E_a^{RR} + \lambda_C S^{RR} - \varepsilon E^{RR} \end{aligned}$$

The equations for SARS-CoV-2 exposed individuals (with antibiotic treatment):

$$\begin{aligned} \frac{dE_a}{dt} &= -(\lambda_{XR} + \lambda_{XRR}) E_a + \tau a E - r E_a + \lambda_C S_a - \varepsilon E_a \\ \frac{dE_a^S}{dt} &= -(\gamma^S + \omega) E_a^S + \tau a E^S - k \lambda_R E_a^S + \lambda_C S_a^S - \varepsilon E_a^S \\ \frac{dE_a^R}{dt} &= -\gamma^R E_a^R + \lambda_{XR} E_a + \tau a E^R - r E_a^R + \lambda_C E_a^R - \varepsilon E_a^R \\ \frac{dE_a^{SR}}{dt} &= -(\gamma^S + \omega) E_a^{SR} + k \lambda_R E_a^S + 2kc \lambda_R E_a^{SS} + \tau a E^{SR} + \lambda_C S_a^{SR} - \varepsilon E_a^{SR} \\ \frac{dE_a^{SS}}{dt} &= -(\gamma^S + \omega) E_a^{SS} - 2kc \lambda_R E_a^{SS} + \tau a E^{SS} + \lambda_C S_a^{SS} - \varepsilon E_a^{SS} \end{aligned}$$

$$\frac{dE_a^{RR}}{dt} = \lambda_{XRR}E_a + \tau a E_a^{RR} - r E_a^{RR} - \gamma^R E_a^{RR} + \lambda_C S_a^{RR} - \varepsilon E_a^{RR}$$

The equations for SARS-CoV-2 infected individuals (no antibiotic treatment):

$$\begin{aligned} \frac{dI}{dt} = & -(\lambda_{XS} + \lambda_{XR} + \lambda_{XSR} + \lambda_{XSS} + \lambda_{XRR})I + \gamma^S(I^S + I^{SS}) + \gamma^R(I^R + I^{SR} + I^{RR} + I_a^R + I_a^{RR}) \\ & + (\gamma^S + \omega)(I_a^S + I_a^{SS}) - (1 - p_{az})\tau a I + r I_a + \varepsilon E - \gamma^C I - p_{az}I + \gamma^R(I_{az}^R + I_{az}^{RR}) \end{aligned}$$

$$\frac{dI^S}{dt} = \lambda_{XS}I - \gamma^S I^S - k\lambda_S I^S - k\lambda_R I^S - (1 - p_{az})\tau a I^S + \varepsilon E^S - \gamma^C I^S - p_{az}I^S$$

$$\frac{dI^R}{dt} = \lambda_{XR}I - \gamma^R I^R - k\lambda_S I^R - k\lambda_R I^R + (\gamma^S + \omega)I_a^{SR} - (1 - p_{az})\tau a I^R + r I_a^R + \varepsilon E^R - \gamma^C I^R - p_{az}I^R$$

$$\begin{aligned} \frac{dI^{SR}}{dt} = & \lambda_{XSR}I - \gamma^R I^{SR} + k\lambda_R I^S + k\lambda_S I^R - kc\lambda_S I^{SR} - kc\lambda_R I^{SR} + 2kc\lambda_R I^{SS} + 2kc\lambda_S I^{RR} \\ & - (1 - p_{az})\tau a I^{SR} + \varepsilon E^{SR} - \gamma^C I^{SR} - p_{az}I^{SR} \end{aligned}$$

$$\frac{dI^{SS}}{dt} = \lambda_{XSS}I - \gamma^S I^{SS} + k\lambda_S I^S + kc\lambda_S I^{SR} - 2kc\lambda_R I^{SS} - (1 - p_{az})\tau a I^{SS} + \varepsilon E^{SS} - \gamma^C I^{SS} - p_{az}I^{SS}$$

$$\frac{dI^{RR}}{dt} = \lambda_{XRR}I - \gamma^R I^{RR} + k\lambda_R I^R + kc\lambda_R I^{SR} - 2kc\lambda_S I^{RR} - (1 - p_{az})\tau a I^{RR} + r I_a^{RR} + \varepsilon E^{RR} - \gamma^C I^{RR} - p_{az}I^{RR}$$

The equations for SARS-CoV-2 infected individuals (with antibiotic treatment):

$$\frac{dI_a}{dt} = -(\lambda_{XR} + \lambda_{XRR})I_a + (1 - p_{az})\tau a I - r I_a + \varepsilon E_a - \gamma^C I_a$$

$$\frac{dI_a^S}{dt} = -(\gamma^S + \omega)I_a^S + (1 - p_{az})\tau a I^S - k\lambda_R I_a^S + \varepsilon E_a^S - \gamma^C I_a^S$$

$$\frac{dI_a^R}{dt} = -\gamma^R I_a^R + \lambda_{XR}I_a + (1 - p_{az})\tau a I^R - r I_a^R + \varepsilon E_a^R - \gamma^C I_a^R$$

$$\frac{dI_a^{SR}}{dt} = -(\gamma^S + \omega)I_a^{SR} + k\lambda_R I_a^S + 2kc\lambda_R I_a^{SS} + (1 - p_{az})\tau a I^{SR} + \varepsilon E_a^{SR} - \gamma^C I_a^{SR}$$

$$\frac{dI_a^{SS}}{dt} = -(\gamma^S + \omega)I_a^{SS} - 2kc\lambda_R I_a^{SS} + (1 - p_{az})\tau a I^{SS} + \varepsilon E_a^{SS} - \gamma^C I_a^{SS}$$

$$\frac{dI_a^{RR}}{dt} = \lambda_{XRR}I_a + (1 - p_{az})\tau a I^{RR} - r I_a^{RR} - \gamma^R I_a^{RR} + \varepsilon E_a^{RR} - \gamma^C I_a^{RR}$$

The equations for SARS-CoV-2 infected individuals (with azithromycin treatment):

$$\frac{dI_{az}}{dt} = p_{az}I - \gamma^C I_{az} - (\lambda_{XR} + \lambda_{XRR})I_{az} + (\gamma^S + \omega)(I_{az}^S + I_{az}^{SS})$$

$$\frac{dI_{az}^S}{dt} = p_{az}I^S - \gamma^C I_{az}^S - (\gamma^S + \omega)I_{az}^S - k\lambda_R I_{az}^S$$

$$\frac{dI_{az}^R}{dt} = p_{az}I^R - \gamma^C I_{az}^R + \lambda_{XR}I_{az} - \gamma^R I_{az}^R + (\gamma^S + \omega)I_{az}^{SR}$$

$$\frac{dI_{az}^{SR}}{dt} = p_{az}I^{SR} - \gamma^C I_{az}^{SR} - (\gamma^S + \omega)I_{az}^{SR} + k\lambda_R I_{az}^S + 2kc\lambda_R I_{az}^{SS}$$

$$\frac{dI_{az}^{SS}}{dt} = p_{az}I^{SS} - \gamma^C I_{az}^{SS} - (\gamma^S + \omega) I_{az}^{SS} - 2kc\lambda_R I_{az}^{SS}$$

$$\frac{dI_{az}^{RR}}{dt} = p_{az}I^{RR} - \gamma^C I_{az}^{RR} + \lambda_{XRR}I_{az} - \gamma^R I_{az}^{RR}$$

The equations for SARS-CoV-2 recovered individuals (no antibiotic treatment):

$$\begin{aligned} \frac{dR}{dt} = & -(\lambda_{XS} + \lambda_{XR} + \lambda_{XSR} + \lambda_{XSS} + \lambda_{XRR})R + \gamma^S (R^S + R^{SS}) \\ & + \gamma^R (R^R + R^{SR} + R^{RR} + R_a^R + R_a^{RR}) + (\gamma^S + \omega) (R_a^S + R_a^{SS}) - \tau aR + rR_a \\ & + \gamma^C I + r_{az}R_{az} + \gamma^R (R_{az}^R + R_{az}^{RR}) \end{aligned}$$

$$\frac{dR^S}{dt} = \lambda_{XSR}R - \gamma^S R^S - k\lambda_S R^S - k\lambda_R R^S - \tau aR^S + \gamma^C I^S + r_{az}R_{az}^S$$

$$\frac{dR^R}{dt} = \lambda_{XRR}R - \gamma^R R^R - k\lambda_S R^R - k\lambda_R R^R + (\gamma^S + \omega) R_a^{SR} - \tau aR^R + rR_a^R + \gamma^C I^R + r_{az}R_{az}^R$$

$$\begin{aligned} \frac{dR^{SR}}{dt} = & \lambda_{XSR}R - \gamma^R R^{SR} + k\lambda_R R^S + k\lambda_S R^R - kc\lambda_S R^{SR} - kc\lambda_R R^{SR} + 2kc\lambda_R R^{SS} + 2kc\lambda_S R^{RR} \\ & - \tau aR^{SR} + \gamma^C I^{SR} + r_{az}R_{az}^{SR} \end{aligned}$$

$$\frac{dR^{SS}}{dt} = \lambda_{XSS}R - \gamma^S R^{SS} + k\lambda_S R^S + kc\lambda_S R^{SR} - 2kc\lambda_R R^{SS} - \tau aR^{SS} + \gamma^C I^{SS} + r_{az}R_{az}^{SS}$$

$$\frac{dR^{RR}}{dt} = \lambda_{XRR}R - \gamma^R R^{RR} + k\lambda_R R^R + kc\lambda_R R^{SR} - 2kc\lambda_S R^{RR} - \tau aR^{RR} + rR_a^{RR} + \gamma^C I^{RR} + r_{az}R_{az}^{RR}$$

The equations for SARS-CoV-2 recovered individuals (with antibiotic treatment):

$$\frac{dR_a}{dt} = \gamma^C I_a + \tau aR - rR_a - \lambda_{XRR}R_a - \lambda_{XRR}R_a$$

$$\frac{dR_a^S}{dt} = \gamma^C I_a^S + \tau aR^S - (\gamma^S + \omega) R_a^S - k\lambda_R R_a^S$$

$$\frac{dR_a^R}{dt} = \gamma^C I_a^R + \tau aR^R - rR_a^R + \lambda_{XRR}R_a - \gamma^R R_a^R$$

$$\frac{dR_a^{SR}}{dt} = \gamma^C I_a^{SR} + \tau aR^{SR} - (\gamma^S + \omega) R_a^{SR} + k\lambda_R R_a^S + 2kc\lambda_R R_a^{SS}$$

$$\frac{dR_a^{SS}}{dt} = \gamma^C I_a^{SS} + \tau aR^{SS} - (\gamma^S + \omega) R_a^{SS} - 2kc\lambda_R R_a^{SS}$$

$$\frac{dR_a^{RR}}{dt} = \gamma^C I_a^{RR} + \tau aR^{RR} - rR_a^{RR} + \lambda_{XRR}R_a - \gamma^R R_a^{RR}$$

The equations for SARS-CoV-2 recovered individuals (with azithromycin treatment):

$$\frac{dR_{az}}{dt} = \gamma^C I_{az} - r_{az}R_{az} - \lambda_{XRR}R_{az} - \lambda_{XRR}R_{az} + (\gamma^S + \omega) (R_{az}^S + R_{az}^{SS})$$

$$\frac{dR_{az}^S}{dt} = \gamma^C I_{az}^S - r_{az}R_{az}^S - (\gamma^S + \omega) R_{az}^S - k\lambda_R R_{az}^S$$

$$\begin{aligned} \frac{dR_{az}^R}{dt} &= \gamma^C I_{az}^R - r_{az} R_{az}^R + \lambda_{XR} R_{az} - \gamma^R R_{az}^R + (\gamma^S + \omega) R_{az}^{SR} \\ \frac{dR_{az}^{SR}}{dt} &= \gamma^C I_{az}^{SR} - r_{az} R_{az}^{SR} - (\gamma^S + \omega) R_{az}^{SR} + k\lambda_R R_{az}^S + 2kc\lambda_R R_{az}^{SS} \\ \frac{dR_{az}^{SS}}{dt} &= \gamma^C I_{az}^{SS} - r_{az} R_{az}^{SS} - (\gamma^S + \omega) R_{az}^{SS} - 2kc\lambda_R R_{az}^{SS} \\ \frac{dR_{az}^{RR}}{dt} &= \gamma^C I_{az}^{RR} - r_{az} R_{az}^{RR} + \tau_a R^{RR} - r_a R_a^{RR} + \lambda_{XRR} R_a - \gamma^R R_a^{RR} \end{aligned}$$

The equations for invasive pneumococcal disease (IPD) incidence caused by sensitive and resistant strains:

$$\begin{aligned} \frac{dIPD^S}{dt} &= p_{inv} IPD_{risk} \left(S^S + S^{SS} + \frac{1}{2} S^{SR} + E^S + E^{SS} + \frac{1}{2} E^{SR} + I^S + I^{SS} + \frac{1}{2} I^{SR} + R^S + R^{SS} + \frac{1}{2} R^{SR} \right) \\ \frac{dIPD^R}{dt} &= p_{inv} IPD_{risk} \left(S^R + S^{RR} + \frac{1}{2} S^{SR} + E^R + E^{RR} + \frac{1}{2} E^{SR} + I^R + I^{RR} + \frac{1}{2} I^{SR} + R^R + R^{RR} \right. \\ &\quad \left. + \frac{1}{2} R^{SR} + S_a^R + S_a^{RR} + S_a^{SR} + E_a^R + E_a^{RR} + E_a^{SR} + I_a^R + I_a^{RR} + I_a^{SR} \right. \\ &\quad \left. + R_a^R + R_a^{RR} + R_a^{SR} + I_{az}^R + I_{az}^{RR} + I_{az}^{SR} + R_{az}^R + R_{az}^{RR} + R_{az}^{SR} \right) \end{aligned}$$

Equations for the prevalence of pneumococcal carriage in the population:

Prevalence of antibiotic-sensitive pneumococcal carriage is calculated as:

$$\begin{aligned} S_{prop} = & \left(S^S + \frac{1}{2} S^{SR} + S^{SS} + S_a^S + \frac{1}{2} S_a^{SR} + S_a^{SS} + E^S + \right. \\ & \frac{1}{2} E^{SR} + E^{SS} + E_a^S + \frac{1}{2} E_a^{SR} + E_a^{SS} + I^S + \frac{1}{2} I^{SR} + I^{SS} + I_a^S + \\ & \frac{1}{2} I_a^{SR} + I_a^{SS} + I_{az}^S + \frac{1}{2} I_{az}^{SR} + I_{az}^{SS} + R^S + \frac{1}{2} R^{SR} + R^{SS} + R_a^S + \\ & \left. \frac{1}{2} R_a^{SR} + R_a^{SS} + R_{az}^S + \frac{1}{2} R_{az}^{SR} + R_{az}^{SS} \right) / Total\ carriage \end{aligned}$$

Prevalence of antibiotic-resistant pneumococcal carriage is calculated as:

$$\begin{aligned} R_{prop} = & \left(S^R + \frac{1}{2} S^{SR} + S^{RR} + S_a^R + \frac{1}{2} S_a^{SR} + S_a^{RR} + E^R + \right. \\ & \frac{1}{2} E^{SR} + E^{RR} + E_a^R + \frac{1}{2} E_a^{SR} + E_a^{RR} + I^R + \frac{1}{2} I^{SR} + I^{RR} + I_a^R + \\ & \frac{1}{2} I_a^{SR} + I_a^{RR} + I_{az}^R + \frac{1}{2} I_{az}^{SR} + I_{az}^{RR} + R^R + \frac{1}{2} R^{SR} + R^{RR} + R_a^R + \\ & \left. \frac{1}{2} R_a^{SR} + R_a^{RR} + R_{az}^R + \frac{1}{2} R_{az}^{SR} + R_{az}^{RR} \right) / Total\ carriage \end{aligned}$$

Total pneumococcal carriage is calculated as:

$$Total\ carriage = S_{prop} + R_{prop}$$

Prevalence of total pneumococcal carriage is calculated as:

$$Total_{prop} = Total\ carriage / N$$

Equations for within-host interactions:

Invasive pneumococcal disease (IPD) incidence implementing within-host interactions is only accounted for in the equations for IPD incidence outside of the model equations, and hence has no impact on model dynamics.

Daily IPD incidence, for the antibiotic-resistant strain is calculated as:


$$\begin{aligned} \frac{dIPD^R}{dt} = & p_{inv}IPD_{risk} \left(S^R + S^{RR} + \frac{1}{2}S^{SR} + E^R + E^{RR} + \frac{1}{2}E^{SR} + \right. \\ & \psi_c \left(I^R + I^{RR} + \frac{1}{2}I^{SR} \right) + R^R + R^{RR} + \frac{1}{2}R^{SR} + S_a^R + \\ & S_a^{RR} + S_a^{SR} + E_a^R + E_a^{RR} + E_a^{SR} + \\ & \psi_c \left(I_a^R + I_a^{RR} + I_a^{SR} \right) + R_a^R + R_a^{RR} + R_a^{SR} + \\ & \left. \psi_c \left(I_{az}^R + I_{az}^{RR} + I_{az}^{SR} \right) + R_{az}^R + R_{az}^{RR} + R_{az}^{SR} \right) \end{aligned}$$

where p_{inv} represents the bacterial invasion rate or progression of carriage to invasive disease and ψ_c represents the co-infection interaction term that increases the rate of progression to invasive disease among colonized individuals who are also infected with SARS-CoV-2.

Daily IPD incidence for the antibiotic-sensitive strain is calculated as:

$$\begin{aligned} \frac{dIPD^S}{dt} = & p_{inv}IPD_{risk} \left(S^R + S^{RR} + \frac{1}{2}S^{SR} + E^R + E^{RR} + \frac{1}{2}E^{SR} \right. \\ & + \psi_c \left(I^R + I^{RR} + \frac{1}{2}I^{SR} \right) + R^R + R^{RR} + \frac{1}{2}R^{SR} + S_a^R \\ & + S_a^{RR} + S_a^{SR} + E_a^R + E_a^{RR} + E_a^{SR} \\ & + \psi_c \left(I_a^R + I_a^{RR} + I_a^{SR} \right) + R_a^R + R_a^{RR} + R_a^{SR} \\ & \left. + \psi_c \left(I_{az}^R + I_{az}^{RR} + I_{az}^{SR} \right) + R_{az}^R + R_{az}^{RR} + R_{az}^{SR} \right) \end{aligned}$$

Due to large uncertainty in the values of ψ_c we considered broad range in our analysis estimated from prior modelling studies (Domenech de Cellès et al., 2019; Opatowski et al., 2013). In the context of ecological interactions between *S. pneumoniae* and influenza, estimations show that influenza co-infection increases the rate of progression from *S. pneumoniae* colonization to invasive pneumococcal disease between 49 and 146-fold, on average, depending on the age group (Domenech de Cellès et al., 2019; Opatowski et al., 2013). Therefore, we implemented the range $1 < \psi_c < 100$ for SARS-CoV-2.




Appendix 2—figure 1. Hypothetical within-host interactions in scenario S19 promote the incidence of antibiotic-resistant invasive pneumococcal disease (IPD). (A) Impacts of ecological interactions between pathogens. When SARS-CoV-2 infection leads to faster progression from pneumococcal colonization to disease, surges in COVID-19 cases accompanied by increasing levels of azithromycin use lead to substantial increases in the daily incidence of IPD. (B) Annual changes in the incidence of antibiotic-resistant IPDs. Appendix 2—figure 1 continued on next page


Appendix 2—figure 1 continued

antibiotic-resistant IPD. (B) Annual excess in cumulative IPD incidence due to synergistic within-host ecological interactions. A rate of disease progression increased by a factor (no within-host interaction) and in scenario S19 applied to the general population resulted in approximately 0.06 and 0.75 additional cases of antibiotic-resistant disease per 100,000 inhabitants over the course of one year, respectively, compared to the scenario S19 assuming no within-host interaction and no azithromycin use indicated by the black arrow (1.17 cases/100,000 inhabitants).

A SARS-CoV-2 transmission and infection:



B Pneumococcal carriage transmission and progression to invasive pneumococcal disease within each of the SEIR model compartments:



Appendix 2—figure 2. Model schematic describing co-circulation of SARS-CoV-2 infection and pneumococcal carriage transmission. (A) Individuals in each of the SARS-CoV-2 transmission model compartments (S, E, I, R) can be either (B) uncolonized (U) or colonized by the bacteria (C^S, C^R, C^{SS}, C^{RR}, C^{SR}) with or without concomitant antibiotic treatment (subscript _{atb} denotes compartments exposed to antibiotics – both standard baseline antibiotic exposure and azithromycin exposure). Full list of model parameters can be found in **Appendix 2—table 2**.

Appendix 2—table 1. Total number of invasive *S. pneumoniae* isolates from blood or cerebrospinal fluid tested in 2019 and 2020 and reported to EARS-Net (European Antimicrobial Resistance Surveillance Network).

Country	No. of invasive <i>Streptococcus pneumoniae</i> isolates in the EU/EEA		% decrease in the total number of reported invasive isolates from 2019–2020
	2019	2020	
Austria	550	301	45.3%
Belgium	1548	858	44.6%
Bulgaria	46	28	39.1%
Croatia	156	55	64.7%
Czechia	387	204	47.3%
Denmark	601	351	41.6%
Estonia	161	80	50.3%
Finland	678	293	56.8%
France	1264	668	47.2%
Germany	2035	1314	35.4%
Hungary	222	124	44.1%
Iceland	44	20	54.5%
Ireland	348	136	60.9%
Italy	1351	685	49.3%
Latvia	79	42	46.8%
Lithuania	120	96	20.0%
Luxembourg	38	24	36.8%
Malta	27	16	40.7%
Netherlands	1552	997	35.8%
Norway	507	243	52.1%
Poland	364	165	54.7%
Portugal	983	588	40.2%
Romania	107	42	60.7%
Slovakia	40	15	62.5%
Slovenia	283	172	39.2%
Spain	1038	611	41.1%
Sweden	1071	551	48.6%
United Kingdom	3468	1412	59.3%

Appendix 2—table 2. Summary of the model parameters.

Symbol	Interpretation	Value(s)	References
SARS-CoV-2 infection parameters:			
β_C	transmission rate of SARS-CoV-2	0.46 days ⁻¹	<i>Liu et al., 2020</i>
γ^c	SARS-CoV-2 recovery rate (mild cases)	1/7 days ⁻¹	<i>Lauer et al., 2020; Rhee et al., 2020</i>

Appendix 2—table 2 Continued on next page

Appendix 2—table 2 Continued

Symbol	Interpretation	Value(s)	References
ϵ	SARS-CoV-2 incubation rate (latent period from exposed to infectious state)	1/5 days ⁻¹	Elias et al., 2021
θ_c	Relative risk of SARS-CoV-2 transmission due to lockdown implementation	0.23	Salje et al., 2020
Pneumococcal colonization and invasion parameters:			
β_s	transmission rate of antibiotic-sensitive strain	0.056 days ⁻¹ 0.046 days ⁻¹ 0.034 days ⁻¹	Davies et al., 2019; Olesen et al., 2020
f	fitness of antibiotic-resistant strain (assuming there is a fitness cost on transmissibility)	0.9652 0.949 0.926	Dagan et al., 2008; Melnyk et al., 2015
β_f	transmission rate of antibiotic-resistant strain		calculated
θ_β	Relative risk of pneumococcal transmission due to lockdown implementation	1 or 0.75	assumed
$\gamma^S = \gamma^R = \gamma^{SS} = \gamma^{RR} = \gamma^{SR}$	rate of natural bacterial clearance (assumed to be the same for antibiotic-sensitive and -resistant strains)	1/20 days ⁻¹ 1/30 days ⁻¹ 1/45 days ⁻¹	Abdullahi et al., 2012; Davies et al., 2019; Ekdahl et al., 1997; Högberg et al., 2021 Melegaro et al., 2004
q	relative infectiousness with each strain for dually colonized	0.5	assumed Colijn et al., 2010
c	fraction of dually colonized returning to single-colonized upon reinfection	0.5	assumed (Colijn et al., 2010)
r	probability of acquiring secondary bacterial carriage	0.5	assumed (Colijn et al., 2010)
p_s	probability of transmitting antibiotic-sensitive strain	0.5	assumed (Colijn et al., 2010)
p_{single}	probability of a single infection	0.5	assumed (Colijn et al., 2010)
p_{inv}	pneumococcal invasion rate (summer and winter)	[3x10 ⁻⁶ day ⁻¹ , 9x10 ⁻⁶ day ⁻¹] in the elderly and general population, and [1x10 ⁻⁶ day ⁻¹ , 2.5x10 ⁻⁶ day ⁻¹] in <5 years-old	Domenech de Cellès et al., 2019; Opatowski et al., 2013
$S^S + S^R$	initial states – initial prevalence of the total pneumococcal carriage (antibiotic-sensitive and -resistant) in different populations	10% 20% 30%	Cohen et al., 2023; Rose et al., 2021; Rybak et al., 2022; Tinggaard et al., 2023; Wang et al., 2017
Antibiotic exposure parameters:			
ω	rate of antibiotic-induced pneumococcal clearance for sensitive strains(1/time before antibiotic action)	1/3 days ⁻¹	Kuitunen et al., 2023

Appendix 2—table 2 Continued on next page

Appendix 2—table 2 Continued

Symbol	Interpretation	Value(s)	References
r	rate of return to antibiotic unexposed compartment (1/duration of antibiotic treatment)	1/7 days ⁻¹	Grant and Saux, 2021; Kuitunen et al., 2023
r_{az}	rate of return to antibiotic unexposed compartment (1/the remainder of how long azithromycin stays in the body)	1/11.5 days ⁻¹	calculated (Foulds et al., 1990; Girard et al., 2005)
τ	baseline rate of antibiotic exposure in the community (France)	0.0014 average daily ppc (prescriptions per capita)	Bara et al., 2022
a	A reduction factor for antibiotic exposure in the community resulting from changes in healthcare-seeking behavior in response to the COVID-19 pandemic	[0.51, 0.77, 0.84]to represent annual 13%, 18%, and 39% decrease observed in France	Bara et al., 2022
p_{az}	A proportion of COVID-19 infected individuals in the community receiving azithromycin	[0–0.20]testing between 0% and 20%	Tsay et al., 2022; Wittman et al., 2023
Pathogenicity (invasive pneumococcal disease risk):			
IPD_{risk}	A reduction factor for the risk of developing an invasive pneumococcal disease (IPD) due to the absence of influenza-like-illnesses (ILIs) after lockdown implementation	1 (pre-lockdown) 0.2 (lockdown) 0.4 (post-lockdown) for an average of 0.5 in 2020	Shaw et al., 2023